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SELECTIVE TOXICITY OF MX106-4C, A SURVIVIN INHIBITOR, TO ABCB1 




 Multidrug resistance (MDR) is a major challenge in colon cancer chemotherapy, 
which is typically mediated by the overexpression of ATP-binding cassette (ABC) 
transporters, particularly ABCB1 (P-gp, MDR1). The application of ABCB1 inhibitors to 
overcome ABCB1-mediated MDR has been disappointing in the clinical settings. As an 
alternative approach, a synthetic analog of survivin inhibitor MX106, MX106-4C, was 
identified as a potent collateral sensitivity (CS) agent that selectively exerted more than 
10-fold cytotoxicity on ABCB1 positive MDR colon cancer cell lines compared to cell 
lines with low ABCB1 expression. Biochemical assays revealed that MX106-4C did not 
affect the ATPase activity or the efflux function of ABCB1. Short-term (up to 72 h) 
incubation with MX106-4C significantly downregulated ABCB1 expression at the 
transcriptional level but not protein level, whereas long-term (14 d) incubation with 
MX106-4C significantly downregulated ABCB1 protein expression. These findings 
suggest an indirect interaction and regulation between MX106-4C and ABCB1.  However, 
the selective toxicity of MX106-4C could be reversed by an ABCB1 inhibitor, knockout 
of ABCB1, or ABCB1 mutation with impaired function, indicating that the selective 
 
cytotoxicity was ABCB1 expression and function dependent. Therefore, MX106-4C may 
interact with an ABCB1-dependent downstream event. Further studies demonstrated that 
the selective cytotoxic effects of MX106-4C were associated with cell cycle arrest at 
G0/G1 phase and apoptosis, possibly via survivin inhibition and activation of caspases-3/7. 
Bioinformatic analysis indicated potential involvement of the p21-CDK6-pRb 
phosphorylation pathway in MX106-4C-induced cell cycle arrest. Anti-cancer efficacy and 
safety tests demonstrated that MX106-4C had good selectivity against ABCB1 positive 
colon cancer cells compared to normal colon cells. The selective toxicity of MX106-4C to 
ABCB1 positive colon cancer could be retained in multicellular tumor spheroids that 
mimicked in vitro settings. Besides, MX106-4C could exert a cytotoxic effect 
synergistically with doxorubicin on ABCB1 overexpressing colon cancer cells, and re-
sensitize ABCB1 positive cells to doxorubicin by reducing ABCB1 expression in cell 
population via long term exposure. Overall, this study demonstrates that MX106-4C 
selectively kills ABCB1 positive MDR colon cancer cells and indirectly interacts with 
ABCB1, which provides a clue for CS compound design and a novel strategy to obviate 
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CHAPTER 1 INTRODUCTION 
Colorectal cancer is the third most commonly occurring cancer in males and the second in 
females with an estimated 1.15 million new cases and 576,858 deaths occurring in 2020 
globally, accounting for 5.8% of all cancer-related deaths (Sung et al., 2021). In the United 
States, colorectal cancer ranks third for morbidity and second for mortality among all types 
of cancer, of which more than two-thirds of diagnostic cases are colon cancer (Siegel et al., 
2020). The primary curative therapy for colon cancer is surgery, while chemotherapy is a 
preferred treatment for metastatic colon cancer (Wu, 2018).  Moreover, chemotherapy can 
be adopted to combat colon cancer at different clinical stages and used as adjuvant therapy 
combined with radiotherapy before or after surgery (Dehal et al., 2018; Labianca et al., 
2010; McQuade et al., 2017; Vargas et al., 2014).  
 
Multidrug resistance (MDR) in cancer, which refers to the reduced responsiveness of 
cancer cells to multiple chemotherapeutic drugs that are not structurally or functionally 
related (Singh et al., 2017), has been reported extensively in patients with colon cancer, 
leading to impairment in the chemotherapy success (Hu et al., 2016). MDR phenotype in 
cancer cells can be intrinsic resistance against standard chemotherapy at diagnosis or 
acquired by prolonged exposure to chemotherapy (Kartal-Yandim et al., 2016; Singh et al., 
2017). Various mechanisms have been discovered to be involved in MDR of colon cancer, 
including instability of chromosome (Lee et al., 2011), mutation of drug target (Holohan 
et al., 2013), impaired apoptotic pathways (Hu et al., 2015), and decrease in intracellular 
drug level due to reduced drug uptake or increased drug efflux mediated by transporters 
(Kozovska et al., 2014). In particular, the upregulated expression of ATP-binding cassette 
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(ABC) transporters that function as pumps eliminating drugs from cancer cells is a 
predominant cause of colon cancer MDR (Hu et al., 2016; Kozovska et al., 2014).  
 
The ABC transporter superfamily consists of 49 members categorized into 7 subfamilies, 
which are termed from ABCA to ABCG (Mohammad et al., 2018). At least 15 human ABC 
transporters have been identified to mediate MDR by facilitating anticancer drugs efflux 
out of tumor cells (Li et al., 2016), particularly ABCB1 (P-glycoprotein, P-gp, MDR1), 
ABCC1 (multidrug resistance-associated protein 1, MRP1), and ABCG2 (breast cancer 
resistance protein, BCRP) (Chen et al., 2016; Hu et al., 2016; Kozovska et al., 2014; Robey 
et al., 2018). Among these members, ABCB1 is one of the most common contributors to 
MDR in colon cancer.  
 
ABCB1 is extensively expressed in various types of tissues, particularly at a high level in 
the epithelial cells of the colon, small intestine, kidney proximal tubules, bile ducts, and 
pancreatic ducts (Holohan et al., 2013). Human ABCB1 is a homodimer transmembrane 
glycoprotein with two monomers each including a transmembrane domain (TMD) with six 
transmembrane α-helices and a nucleotide-binding domain (NBD) where ATP is bound 
and hydrolyzed. ATP hydrolysis is essential for drug transport of ABCB1 from the 
intracellular to the extracellular side of the cell (Nandigama et al., 2019). As illustrated in 
Figure 1, the catalytic cycle of ABCB1 drug efflux involves substrate binding at the drug-
binding pocket at TMDs,  closure of TMDs inward, and binding of two ATP molecules to 
NBDs leading to dimerization of NBDs,  Subsequently, TMDs open outward excreting the 
substrate, and ATP molecules are hydrolyzed providing energy for the protein 
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conformational change from inward to outward as well as for the reset to the rest status (Li 
et al., 2016; Wang et al., 2021). With a vast spectrum of substrates, ABCB1 plays an 
important physiological role in protecting tissues by extruding various xenobiotics and 
toxicants (International Transporter et al., 2010). On the other hand, tumors that originated 
from tissues with ABCB1 expressions, such as colorectal epithelium, gain intrinsic 
resistance to many widely used chemotherapeutic drugs that are ABCB1 substrates, such 
as doxorubicin, paclitaxel, and vincristine (Fu & Arias, 2012; Meschini et al., 2000). 
ABCB1 expression can also be induced in cancer cells by long-term exposure to 
chemotherapeutic agents (Ghanbarian et al., 2018; Harmsen et al., 2010), and up-regulation 
of ABCB1 expression has been associated with developed MDR during the course of 
cancer chemotherapy (Hu et al., 2016; Kathawala et al., 2015). 
 
 
Figure 1. Catalytic cycle of drug efflux by ABCB1. 
 
A variety of strategies to overcome ABCB1-mediated MDR have been investigated, 
including the development of drugs with a novel mechanism of action to bypass resistance 
and the development of novel ABCB1 inhibitors that block efflux and restore drug 
accumulation when given with anti-cancer drugs (Mohammad et al., 2018; Zhang et al., 
2021). In particular, the reversal of MDR by ABCB1 modulators has been extensively 
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investigated. Three generations of small molecule ABCB1 inhibitors and some natural 
products considered as the fourth generation ABCB1 inhibitors have been developed (De 
Vera et al., 2019; Efferth et al., 2020). The first generation of ABCB1 inhibitors such as 
verapamil (Futscher et al., 1996) and cyclosporine A (Egashira et al., 1999) had a relatively 
low affinity and selectivity to ABCB1, making the dosages required for ABCB1 inhibition 
likely to cause toxicity and side effects (Dong et al., 2020). The second generation of 
ABCB1 inhibitors was majorly developed by structural modification based on the first-
generation inhibitors of ABCB1 (Palmeira et al., 2012). Examples of the second-generation 
ABCB1 modulators include dexverapamil, which was derived from verapamil (Dagenais 
et al., 2001), and valspodar (PSC 833), an analog of cyclosporin A (Egashira et al., 1999).  
These drugs had a higher potency, better ABCB1 selectivity, and lower toxicity compared 
to the first generation, however, they also had significant inhibitory effects on cytochrome 
P450 enzymes, thereby increasing the likelihood of problematic drug-drug interactions 
with the co-administrative chemotherapeutic drugs (Gottesman et al., 2009; Li et al., 2016). 
The third generation ABCB1 inhibitors, such as zosuquidar (LY335979) (Sandler et al., 
2004) and tariquidar (XR9576) (Patel et al., 2011), were developed on the basis of 
quantitative structure-activity relationship (QSAR) analysis to improve potency and 
minimize effects on cytochrome P450 enzymes (Nobili et al., 2006; Silva et al., 2015). 
Despite promising pre-clinical results demonstrated for third-generation ABCB1 inhibitors, 
subsequent clinical trials turned out to be disappointing due to the intrinsic toxicity or 
absence of improvements on the overall survival of patients (Coley, 2010; Cripe et al., 
2006). Furthermore, natural products such as curcumin, flavonoids, alkaloids, and marine 
sponge extracts that have shown inhibitory effects on ABCB1 function are generally 
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considered as the fourth generation ABCB1 modulator (Kumar & Jaitak, 2019). Several 
natural products with ABCB1 inhibiting efficacy, such as tetrandrine and macrolide 
eribulin mesylate, have been advanced to clinical trials for MDR modulation where results 
are awaited (Abraham et al., 2012; N & K, 2018). Currently, none of the ABCB1 inhibitors 
has been approved by the Food and Drug Administration (FDA) as a combination of a 
chemotherapeutic drug. Therefore, alternative approaches are urgently needed to 
circumvent or resolve cancer MDR mediated by ABCB1.  
 
In the past decade, the discovery of small molecules that have selective toxicity against 
ABCB1-expressing cells but not the non-resistant parental cells, a characteristic known as 
collateral sensitivity (CS), has introduced an alternative strategy to surmount MDR in 
ABCB1 positive cancer (Efferth et al., 2020; Hall et al., 2009; Pluchino et al., 2012). The 
identification of CS compounds with high selectivity and potency may help prevent MDR 
when used with chemotherapeutic drugs, or re-sensitize MDR tumors to conventional 
treatment regimens by selectively killing MDR cells in a heterogeneous tumor population 
(Pluchino et al., 2012). However, research discoveries of CS are still rather limited, and 
the complex mechanisms of action of CS compounds have not been elucidated due to 
insufficient experimental evidence. Major mechanisms identified for the action of CS 
agents include 1) reactive oxygen species (ROS) production by futile hydrolysis of ATP, 
2) inhibition of ATP production, and 3) induction of plasma membrane perturbation 




Verapamil was first recognized as a re-sensitizing agent against ABCB1-mediated MDR 
when co-administrated with chemotherapeutic agents. In 1986, Warr et al. first reported 
that verapamil showed to be a CS agent by exerting higher toxicity to ABCB1 
overexpressing vincristine-resistant subline of Chinese hamster ovary (CHO) cells (VCR/T 
subline) in the absence of other cytotoxic agents (Warr et al., 1986). Albeit that verapamil 
is more toxic to the ABCB1 overexpressing VCR/T subline, the accumulation of verapamil 
in VCR/T cells was found lower than that in parental CHO cells due to the efflux of 
verapamil by ABCB1, and the CS effect was found to be independent of verapamil’s 
function on blocking calcium channel, indicating that the CS effect may be related to 
verapamil-ABCB1 interaction (Cano-Gauci & Riordan, 1987; Warr et al., 1986). Further 
studies revealed that the selective cytotoxicity on ABCB1 overexpressing cells mediated 
by verapamil was dependent on ABCB1 ATPase function and expression of ABCB1 
(Karwatsky et al., 2003; Laberge et al., 2009). Based on the dual role of verapamil as a 
substrate as well as an inhibitor of ABCB1, which both can stimulate ATPase activity of 
ABCB1, it had been hypothesized that verapamil may induce the CS effect by causing 
futile hydrolysis of ATP leading to ROS production and depletion of ATP (Callaghan et 
al., 2014; Karwatsky et al., 2003; Laberge et al., 2009). Although the CS effect of verapamil 
has been only observed in CHO cells but not in human cancer cells, and the cardiac toxicity 
of verapamil has limited its usage in reversing cancer MDR under clinical setting, the 
discovery of the CS effect on ABCB1 positive cells gave a new idea on targeting ABCB1 
overexpressing MDR cancer. More CS agents have been discovered and reported in the 
past 10 years, which has promoted a deeper understanding of the mechanism for CS effects 
against ABCB1 positive cancer and further facilitated the development of this novel 
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approach for combating ABCB1-mediated cancer MDR. Unsurprisingly, different CS 
agents can have different types of interaction with ABCB1 to reach the same outcome--
selectively killing ABCB1 overexpressing cancer cells. Nakagawa-Goto and colleagues 
have demonstrated that desmosdumotin B and its analogs were able to selectively kill 
vincristine-selected ABCB1 positive human epidermoid cancer cells (Nakagawa-Goto et 
al., 2008) and liver cancer cells (Kuo et al., 2011). Similar to verapamil, the CS effect of 
desmosdumotin B has been shown to rely on the expression of functional ABCB1 
(Nakagawa-Goto et al., 2010). However, as a flavonoid derivative, desmosdumotin B was 
considered to have an inhibitory effect on ABCB1 ATPase and reduce ABCB1 drug efflux 
activity (Sun et al., 2009). Further study revealed that desmosdumotin B derivatives may 
induce selective toxicity through directly interacting with ABCB1 thereby inhibiting 
downstream mTOR pathways and downregulating molecular chaperone GRP78 (Kuo et 
al., 2011). ROS production has been suggested as an important mechanism for CS agents, 
but the cause of ROS production can be more complex than simply inducing futile ATP 
hydrolysis. Dp44mT (di-2-pyridylketone 4,4-dimethyl-3-thiosemicarbazone) is a redox-
active agent which can induce hydroxyl radicals by chelating iron (Lovejoy et al., 2011). 
It has been shown that Dp44mT was selectively toxic to multiple types of ABCB1 positive 
MDR cancer in vitro and in vivo by “hijacking” lysosomal ABCB1 as an ABCB1 substrate, 
which enables the compound to enter lysosome and induce oxidative stress in the lysosome 
resulting in cell death (Jansson et al., 2015). Some CS agents may exert selective toxicity 
without having direct interaction with ABCB1. An example is NSC73306 and its analogs, 
which have been demonstrated to produce ABCB1-dependent CS effects on various types 
of cancer cells expressing endogenous or selection-induced ABCB1 expression, without 
 
 8 
affecting ABCB1 ATPase or ABCB1 efflux activity (Ludwig et al., 2006). Heffeter et al. 
(2007) have also reported a lanthanum compound KP772 that had CS effects against 
ABCB1 overexpressing cancers without direct interaction with ABCB1 (Heffeter et al., 
2007). However, the precise mechanism of action for NSC73306 and KP772 has not been 
fully elucidated. 
 
MX106 is a recently developed survivin inhibitor with potent anti-cancer efficacy (Wang 
et al., 2018; Xiao et al., 2015). Recently, in examining the anti-cancer effects of synthesized 
analogs of MX106, we unexpectedly found that MX106 and a number of its analogs 
exhibited CS by killing ABCB1-overexpressing MDR colon cancer cells, SW620/Ad300, 
selectively over the parental drug-sensitive cells, SW620 (Xiao et al., 2017). Among those 
compounds, MX106-4C (5-(((2-bromo-4-methylbenzyl)oxy)methyl)-7-(pyrrolidine-l- 
ylmethyl)quinolin-8-ol)) (Figure 2) has been identified as a leading compound with the 
most potent selective toxicity against ABCB1 positive colon cancer cells. The preliminary 
findings suggested that MX106-4C may not directly interfere with ABCB1 function as a 
substrate or an inhibitor since it did not affect ABCB1 ATPase activity or substrate efflux 
function. Although the observed characteristics of MX106-4C are similar to two other CS 
compounds against ABCB1, NSC73306 and KP772, there may be a tremendous difference 
in how the compound affects ABCB1-dependent biological events according to the 
reported mechanism variations from previously discovered CS agents. Therefore, it is 
necessary to undertake mechanistic studies to elucidate how MX106-4C exert selective 





Figure 2. Chemical structures of MX106 and MX106-4C. 
 
Survivin (BIRC5), which is the smallest member of the inhibitor-of-apoptosis proteins 
(IAPs) family, is frequently overexpressed in various cancers and has been associated with 
chemoresistance and poor prognosis in cancer patients (Altieri, 2015; Peery et al., 2017). 
The oncogenic roles of survivin mainly depend on its function of inhibiting apoptosis such 
as inhibiting the activation of caspases-3 and 7 and regulating mitosis by affecting cell 
cycle via binding to CDK4 (Garg et al., 2016). Increased Survivin correlates with poor 
prognosis, tumor recurrence, and drug resistance in various human cancers (Coumar et al., 
2013; Zaffaroni & Daidone, 2002). Therefore, the elevated expression of survivin in most 
cancer cells makes it an attractive target for cancer treatment. It has been reported that 
survivin may interact with ABCB1. Souza et al. discovered cytoplasmic co-localization of 
ABCB1 and survivin in leukemia cells, suggesting a functional association between these 
two proteins in apoptosis control (Souza et al., 2011). Liu et al have demonstrated that 
overexpression of survivin in human breast adenocarcinoma cells MCF-7 reduced 
doxorubicin accumulation in cells with upregulation of ABCB1 mRNA level, whilst down 
regulation of survivin in its doxorubicin-resistant cell line MCF-7/ADR could 
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downregulate ABCB1 mRNA level and increase the drug accumulation thereby re-
sensitizing cells to doxorubicin (Liu et al., 2010). However, Shi et al. (2007) found that the 
protein expression level of ABCB1 was not affected by upregulating or down regulating 
survivin in KB cell line, MCF-7 cell line, and their corresponding ABCB1 overexpressing 
MDR cell lines KBv200 and MCF-7/ADR, which suggested that survivin in MDR cancer 
cells may not interact with ABCB1 directly (Shi et al., 2007). Similarly, inhibition of 
ABCB1 was found to downregulate the transcription activity of survivin but not the protein 
level, indicating that there may be other pathways associating survivin and ABCB1 
indirectly in MDR cancer (Liu et al., 2010). It is worthwhile to ascertain whether there is a 
possible mechanism of action of MX106-4C on ABCB1 via modulating survivin. 
 
Therefore, the main aims of this project are: 1) to elucidate the mechanism of action of 
MX106-4C in ABCB1 positive colon cancer cells, including ROS production, the 
interaction with ABCB1, survivin, and the possible interplay between ABCB1 and survivin 
involved inducing cell death; 2) to evaluate the efficacy of MX106-4C using co-
administrative treatment with anti-cancer drugs or as a re-sensitizing agent in colon cancer 
cells. Shedding light on the mechanisms of action and the anti-cancer efficacy for 
compound MX106-4C can provide information for CS compound design and potential 




CHAPTER 2 MATERIALS AND METHODS 
2.1 Chemicals and Reagents 
Dulbecco’s modified Eagle’s medium (DMEM), fetal bovine serum (FBS), and 0.25% 
trypsin-EDTA were purchased from Corning Inc. (New York, NY). Eagle's minimum 
essential medium (EMEM) was purchased from ATCC (American Type Culture Collection, 
Manassas, VA). Doxorubicin, tariquidar, formaldehyde, Triton X-100, 3-(4, 5-
dimethylthiazol-yl)-2, 5-diphenyltetrazolium bromide (MTT), agarose, N-acetylcysteine, 
and the mouse monoclonal antibody (mAb) for ABCB1 (clone F4) were purchased from 
Sigma Chemical Co. (St. Louis, MO). Geneticin (G418) and cisplatin were obtained from 
Enzo Life Sciences (Farmingdale, NY). The radiolabeled drug [3H]-paclitaxel (31 Ci/mmol) 
was ordered from Moravek Biochemicals, Inc. (Brea, CA). Annexin V-FITC, annexin-V 
binding buffer, and PI/RNase staining buffer were from BD Biosciences (San Jose, CA). 
The primary antibodies for survivin (clone 71G4B7 rabbit mAb), p53 (clone 1C12 mouse 
mAb), p21 (clone 12D1 rabbit mAb), CDK4 (clone D9G3E rabbit mAb), CDK6 (clone 
D4S8S rabbit mAb), cyclin D1 (clone E3P5S rabbit mAb), pRb (clone 4H1 mouse mAb), 
phosphorylated pRb (Ser807/811, rabbit mAb), and β-actin (clone 13E5 rabbit mAb), and 
the horseradish peroxidase-conjugated secondary antibodies were purchased from Cell 
Signaling Technology (Danvers, MA). Phosphate buffer saline (PBS), dimethyl sulphoxide 
(DMSO), Trizol reagent, the mouse mAb for glyceraldehyde phosphate dehydrogenase 
(GAPDH clone G1AR), the Alexa Fluor 488-labeled secondary antibody (anti-mouse), 
4,6-diamidino-2-phenylindole (DAPI), and other reagents were ordered from Thermo 




2.2 Cell Lines and Cell Culture 
The HCT-15 cell line originated from human colon adenocarcinoma was purchased from 
ATCC (American Type Culture Collection, Manassas, VA). The human colon 
adenocarcinoma SW620 and SW620/Ad300 cell lines were kind gifts from Dr. Susan E. 
Bates (Columbia University, NY) and Dr. Robert W. Robey (NCI, NIH, MD). The drug-
induced ABCB1 overexpressing SW620/Ad300 cell line was derived from the parental 
SW620 cell line after prolonged exposure to gradually increasing concentration of 
doxorubicin up to 300 ng/mL (Lai et al., 1991). The human epidermoid carcinoma cell line 
KB-3-1 and the derived ABCB1 overexpressing KB-C2 cell line were kindly provided by 
Dr. Shinichi Akiyama (Kagoshima University, Japan). The KB-C2 cell line was established 
from the KB-3-1 cell line by a step-wise selection of KB-3-1 in increasing concentrations 
of colchicine up to 2 μg/mL (Akiyama et al., 1985). All of the aforementioned cell lines 
were cultured in 10% FBS-supplemented DMEM with the addition of 100 unit/mL 
penicillin/streptomycin. The SW620/Ad300 and KB-C2 cell lines were respectively 
maintained in a complete culture medium containing 300 ng/mL doxorubicin or 2 μg/mL 
colchicine, which were switched to drug-free medium at least 2 weeks before experiments. 
The stably transfected cell lines HEK293/pcDNA 3.1 and HEK293/ABCB1, which were 
established by transfecting HEK293 cells with either the empty pcDNA3.1 vector or the 
vector containing full-length ABCB1, were gifts from Dr. Robert W. Robey (NCI, NIH, 
MD). The transfected cell lines were cultured in 10% FBS-supplemented DMEM with the 
addition of the selective agent G418 (2 mg/mL). The human normal colon fibroblast CCD-
18Co cell line was generously given by Dr. Diane Hardej (St. John’s University, NY). The 
CCD-18Co cells were cultured in EMEM supplemented with 10% FBS and 100 unit/mL 
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penicillin/streptomycin. All cell lines were cultured in a 37℃ humidified incubator 
containing 5% CO2. 
 
In addition, the HeLa S3 cell models with or without the expression of wildtype (WT) 
ABCB1 or mutated ABCB1, including untransduced HeLa S3 cell line, HeLa S3 cells 
transiently transduced with WT ABCB1, TM6,12-14A, and TM6,12-14A-EQ mutants, 
respectively, were used to study the role of functional ABCB1 in the selective toxicity of 
MX106-4C. The ABCB1 TM6,12-14A mutant, which was established by substituting a 
group of 14 conserved residues, including seven in both transmembrane helixes 6 and 12, 
with alanine, has impaired efflux and acquired uptake function, while the TM6,12-14A-
EQ mutant has two more mutants at residue E556 and E1201 (both are substituted with 
glutamine) at NBD region required for ATP hydrolysis leading to deficient ATPase 
function of ABCB1 (Sajid et al., 2020). Due to the unstable transduced models and 
limitation on material transferring, experiments involving these cell models, as described 
in section 2.3, were performed by Drs. Suresh V. Ambudkar and Hadiar Rahman in 
National Cancer Institute. 
 
2.3 Cytotoxicity Assay and Combinational Administration Studies 
The MTT assay was performed to determine the ability of compound MX106-4C to 
circumvent ABCB1-mediated drug resistance. Cells were seeded at a density of 5000 
cells/well into 96-well plates and cultured overnight. Then, various concentrations of 
compound MX106-4C were added respectively to the cells for a 72-h incubation. At the 
last 4 h of incubation, 20 µL of the MTT solution (4 mg/mL) was added into each well. At 
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the end of incubation, the medium was replaced by 100 µL of DMSO to dissolve the 
formazan crystals. The plates were well shaken for 10 min, and the absorbance was 
determined at 570 nm using AccuSkan™ GO UV/Vis Microplate Spectrophotometer 
(Fisher Sci., Fair Lawn, NJ). The half-maximal inhibitory concentration (IC50) values were 
calculated from the concentration-response curve to represent the cytotoxicity of the 
compound. The fold of drug resistance was calculated by dividing the IC50 value obtained 
from the ABCB1 overexpressing cells by that from the parental cell line. Doxorubicin and 
cisplatin were also tested as ABCB1 substrate and non-substrate controls, respectively. In 
addition, YM155, a survivin inhibitor that is known as an ABCB1 substrate (Radic-Sarikas 
et al., 2017), was tested to compare with the cytotoxicity of MX106-4C in ABCB1 
overexpressing cells.  
 
In tests involving long-term (14 days) exposure, 50000 cells were seeded into a T25 flask 
and incubated in the growth medium for 24 h to ensure adherence before starting treatment. 
During the 14-day treatment, the culture medium was replaced with a fresh medium 
containing 100 nM MX106-4C every 2-3 days. Cells were allowed to recover in a drug-
free medium after treatment until 70% confluency was reached, then cells were harvested 
and seed onto 96-well plates for cytotoxicity assay. 
 
Cytotoxicity assays with HeLa S3 cells expressing ABCB1, TM6,12-14A, or TM6,12-
14A-EQ mutant were conducted by incubating the cells in 96-well plate with various 
concentrations of compound MX106-4C for 48 h at 37°C, followed by cell viability test 
using Cell Titer Glo reagent kit (Promega). Briefly, 100 µL of CellTiter-Glo reagent was 
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added to each well followed by 2-min shaking to mix and 10-min incubation at room 
temperature. Then, the generated luminescence was measured, and the percentage of the 
control group was used to represent percent survival.  
 
For reversal study, cells were treated with varying concentrations of MX106-4C, 
doxorubicin, or cisplatin, with or without adding 1 µM tariquidar 2 h before the treatment 
started. MTT assay was conducted at the end of the treatment and the IC50 values of a 
compound with or without co-administration of tariquidar were compared to measure the 
reversal effect. For drug combination experiments, cells were co-treated with different 
concentrations of MX106-4C and doxorubicin for 72 h. The cell viability was determined 
by MTT assay as mentioned in the previous paragraph, and the inhibitory effect of each 
combination was measured by the percentage of cell viability reduction compared to the 
control group. The data was further analyzed using CompuSyn software (ComboSyn Inc, 
Paramus, NJ). The combination index (CI) was calculated based on the Chou-Talalay 
method (Chou, 2010): CI = (D)1/(Dx)1 + (D)2/(Dx)2, where (Dx)1 and (Dx)2 represented 
concentrations of MX106-4C and doxorubicin alone to inhibit x% of cell viability while 
(D)1 and (D)2 were concentrations of MX106-4C and doxorubicin in combination to exert 
the same effect, respectively. Synergism, additive effect, and antagonism were indicated 
by CI < 1, =1, and >1, respectively. 
 
2.4 Analysis of Intracellular Accumulation of Compound MX106-4C 
SW620 and SW620/Ad300 cells were seeded into 10 cm culture dishes at a density of 5 × 
106 cells per dish and incubated for 24 h. Then, cells were incubated with complete growth 
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medium containing vehicle control or 1 µM compound MX106-4C for 2 h and 4 h, 
respectively. After incubation, cells were washed with PBS three times and harvested by 
trypsinization. The cell suspensions were centrifuged at 1000 rpm for 5 min and further 
washed three times with PBS. The cell pellets were lysed in 200 µL ice-cold methanol 
(>99%) by vortex-mixing for 2 min followed by centrifuge at 12000 rpm for 4 min. The 
supernatant was subjected to further preparation for LC-MS/MS analysis, meanwhile, the 
pellet was dissolved with 1 mL 0.3 M NaOH and subjected to protein quantification using 
Bradford assay. The supernatant of each sample was filtered through a 0.2-µm filter.  Then, 
20 µL of the supernatant were mixed with 20 µL of internal standard working solution and 
100 µL of acetonitrile. A 2 µL aliquot of the mixture was injected into the LC-MS/MS 
system. ABI-231 was used as an internal standard compound for quantitative analysis. The 
LC-MS/MS detection was performed by Dr. Dejian Ma at the University of Tennessee 
Health Science Center. The compound concentration was normalized by the pellet protein 
quantity.  
  
2.5 ABCB1 ATPase Assay 
The ABCB1 ATPase assay was performed using prepared ABCB1 crude membranes 
vesicles of High-five insect cells as previously described (Ambudkar, 1998). Briefly, the 
ABCB1 membrane vesicles were incubated in ATPase assay buffer with or without 0.3 
mM sodium orthovanadate (Na3VO4), which is an inhibitor of ABCB1 ATPase. Various 
concentrations of compound MX106-4C or paclitaxel (0 – 10 µM) were added to incubate 
with the membranes at 37℃ for 5 min. Then, the ATPase reaction was initiated by adding 
5 mM of Mg-ATP. After incubation for 20 min at 37°C, 100 μL 5% SDS solution were 
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added to terminate the reaction. The amount of inorganic phosphate released was detected 
by spectrophotometry using the phosphomolybdate method. The vanadate-sensitive 
ATPase activity due to the ABCB1 transporter was calculated by comparing the released 
inorganic phosphate content in samples with and without Na3VO4 treatment.  
 
2.6 [3H]-Paclitaxel Accumulation and Efflux Assay 
The effect of compound MX106-4C on the intracellular accumulation and efflux of [3H]-
paclitaxel was determined in SW620 and SW620/Ad300 cells. Cells were incubated at 
37°C in the presence or absence of MX106-4C (50 nM) or tariquidar (50 nM) for 72 h. At 
the end of incubation, the cells were harvested, and cell counting was performed using a 
hematocytometer. The cell suspensions were diluted to the same density for all groups, 
followed by additional 2 h incubation in a medium containing 10 nM [3H]-paclitaxel with 
or without MX106-4C or tariquidar. After incubation, cells were washed with ice-cold PBS 
then incubated in a medium free of [3H]-paclitaxel, with or without MX106-4C or 
tariquidar. At various time points (0, 30, 60, 120 min) cells were harvested and transferred 
into scintillation fluid. The radioactivity was detected using the liquid scintillation counter 
(Packard Instrument, IL). 
 
2.7 Immunofluorescence Assay 
SW620 and SW620/Ad300 cells were seeded at a density of 1 × 105 cells on sterilized glass 
coverslips pretreated with 0.1 mg/mL poly-D-lysine in 6-well plates. After 24 h culturing 
that enabled the cells to stabilize and attach to the glass coverslip, a 72 h incubation with 
vehicle control, 50 or 100 nM MX106-4C was conducted. Thereafter, the cells were 
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washed twice with ice-cold PBS and fixed with 4% paraformaldehyde, followed by 
permeabilization with 0.25% Triton X-100.  Then, the immunofluorescence staining was 
performed following the procedures of 1 h blockage with 6% bovine serum albumin (BSA) 
in PBS, overnight incubation with the monoclonal antibody against ABCB1 at 4°C, PBS 
wash, and 2 h incubation with Alexa Flour 488 rabbit anti-mouse secondary antibody at 
room temperature. To counterstain the nuclei, the cells were further incubated with DAPI 
solution at room temperature for 15 min. After the staining steps, the coverslip with 
attached cells was washed twice with PBS then mounted on a glass slide. 
Immunofluorescence images were taken with an EVOS FL Auto Imaging System (Thermo 
Fisher Scientific Inc., Rockford, IL). 
 
2.8 Reverse Transcription-Quantitative PCR (RT-qPCR) 
Total mRNA of cells was extracted using Trizol reagent following the manufacturer's 
protocol. Total RNA concentrations and purity were determined by the optical density (OD) 
at 260nm and the ratio of OD260nm/OD280nm. Reverse transcription was performed for 
cDNA synthesis. Quantitative gene analysis was performed using the fluorescent dye 
SYBR Select Master Mix (Applied Biosystems, Foster City, CA). The primer sequences 
are listed in Table 1. The PCR reactions were conducted in Aria Mx Real-Time PCR 
System (Agilent Technologies, Santa Clara, CA). The mRNA expression was quantified 






2.9 Western Blotting 
Cells were lysed on ice in lysis buffer (10 mM Tris, 1mM EDTA, 150 mM NaCl, 0.1% 
SDS, 1% Triton X-100 and protease inhibitor cocktail) for 20 min, followed by 
centrifugation at 12,000 x g at 4°C for 20 min. The protein concentration was quantified 
using Pierce BCA Protein Assay Kit (Thermo Fisher Scientific Inc., Rockford, IL). Equal 
amounts of total cell lysates were loaded into an SDS-polyacrylamide gel and then 
electronically transferred to a polyvinylidene difluoride (PVDF) membrane. The 
membrane was blocked in 5% non-fat milk in TBST for 2 h, and then incubated in primary 
antibody overnight at 4°C, followed by the incubation in HRP-linked secondary antibody 
for 2 h at room temperature. The blocking agent and antibody diluting agent were switched 
to 5% BSA in TBST for phosphorylated protein detection to avoid interference from milk 
casein. The signal was detected using enhanced chemiluminescence.  
 
2.10 Knockout of ABCB1 Gene in SW620/Ad300 and HCT-15 Cells 
A CRISPR/Cas9 system was used to construct the ABCB1 gene knockout subline of 
SW620/Ad300 and HCT-15 cell lines, respectively. The custom-designed mammalian 
CRISPR vector was purchased from VectorBuilder Inc. (Chicago, IL). The gRNA of the 
vector targeting the human ABCB1 gene contains a specific 20 bp guide sequence of 5’- 
CGTAATGCTGACGTCATCGC-3’ selected from exon 16 of the human ABCB1. 
Transfection of the ABCB1 targeting vector into SW620/Ad300 and HCT-15 cells was 
performed using Fugene6 transfection reagent (Promega, Madison, WI) according to the 
manufacturer's instructions. Briefly, SW620/Ad300 cells and HCT-15 cells were seeded in 
100 mm dishes with 1 × 106 cells per dish and cultured overnight in DMEM with 10% FBS 
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without antibiotics. Then, 8 µg of plasmid DNA was prepared in 376 µL of Opti-MEM 
medium and mixed with 24 µL of Fugene6 reagent. After a 30-min incubation at room 
temperature, the complex was mixed into the cell culture medium and incubated with the 
cells in a culture incubator for 48 h. At the end of incubation, the transfected cells were 
rinsed with PBS then incubated with the selection medium containing 1.5 mg/mL G418 for 
14 days with the medium changed every three days. Non-transfected cells were used as 
negative controls for the selection process. Single colonies of surviving cells were obtained 
using the limited dilution method and expanded for further study. The knockout of ABCB1 
was further verified by measuring protein expression and mRNA expression levels using 
Western blotting and reverse transcription-quantitative PCR analysis, respectively. 
 
2.11 Cell Apoptosis Assay 
SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells were exposed to MX106-4C 
for 0, 24, 48, 72 h, or 100 nM MX106-4C for 72 h. At the end of the exposure period, the 
apoptotic cells in each group were detected by flow cytometry using BD Pharmingen FITC 
Annexin V apoptosis detection kit following the manufacturer’s instruction. Briefly, cells 
were harvested and washed twice with PBS. Then, cells were stained with Annexin V-
FITC and propidium iodide (PI) in the binding buffer for 15 min in the dark. The 
fluorescence was measured for 30000 events per sample using BD Accuri C6 flow 
cytometer (BD Biosciences, San Jose, CA) at an excitation wavelength of 488 nm through 





2.12 Cell Cycle Analysis 
SW620, SW620/Ad300, SW620/Ad300-ABCB1ko cells were exposed to 50 nM MX106-
4C for 0, 24, 48, 72 h, or 100 nM MX106-4C for 72 h. At the end of treatment, cells were 
harvested and washed twice with ice-cold PBS, followed by a fixation step with ice-cold 
70% ethanol for 30 min on ice. After fixation, cells were collected by centrifugation, 
washed using PBS, then centrifuged again to remove the supernatant.  The cell pellets were 
resuspended with 0.5 mL BD Pharmigen PI/RNase stain buffer and incubated in the dark 
for 15 min at room temperature. The flow cytometric-based cell cycle analysis was 
performed using BD Accuri C6 (BD, Franklin Lakes, NJ) running 30000 events per sample 
at a slow rate. The percentage of cells in each cell cycle phase was determined using BD 
Accuri C6 software.   
 
2.13 Intracellular ROS Measurement 
SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells were incubated with 100 nM 
MX106-4C for 0, 24, 48, 72 h, or 200 nM MX106-4C with or without 5 mM N-
acetylcysteine for 72 h.  Subsequently, cells were harvested, washed with PBS, and 
incubated with ROS indicator CM-H2DCFDA (10 µM) in the dark for 30 min at 37℃. The 
fluorescent product of CM-H2DCFDA generated by the action of intracellular peroxides 
was detected by measuring the fluorescence intensity at excitation wavelength 495 nm and 
emission wavelength 520 nm using Synergy H1 Hybrid plate reader (BioTek, Winooski, 
VT). After reading, the samples were lysed for protein quantification using the BCA assay. 
The fluorescence intensity data were normalized by protein content for each sample. 
2.14 Intracellular GSH Measurement 
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SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells were incubated with 100 nM 
MX106-4C for 0, 24, 48, 72 h, or 200 nM MX106-4C with or without 5 mM N-
acetylcysteine for 72 h. After treatment, cells were harvested using a cell scraper with PBS. 
The cell pellets were collected by centrifugation and homogenized using cold MES buffer 
(0.2 M 2-(N-morpholino) ethanesulphonic acid, 0.05 M phosphate, and 1 mM EDTA, pH 
6.0), followed by centrifuge at 10000 g for 15 min at 4°C. The supernatant was collected 
and split into two portions: a half portion was submitted to intracellular total GSH detection 
using Cayman’s GSH assay kit (Cayman Chemical Inc., Ann Arbor, MI) according to the 
manufacturer’s protocol; the other half portion was subjected to BCA protein quantification 
assay for normalization of data. 
 
2.15 Caspases-3/7 Assay 
SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells were exposed to vehicle 
control or 50 or 100 nM of MX106-4C, or a combination of MX106-4C with 1 µM 
tariquidar, for 72 h. At the end of incubation, cells were harvested and washed with PBS. 
Then, cells were incubated with CellEvent™ Caspase 3/7 Green Detection Reagent 
(Invitrogen), and the caspase-3/7 activity was determined by flow-cytometric measurement 
on the fluorescence product from cleavage of the detection reagent by active caspases-3/7. 
The fluorescence signal was measured 30000 events per sample using BD Accuri C6 flow 
cytometer (BD, Franklin Lakes, NJ) at an excitation wavelength of 488 nm through FL-1 
(533 nm) filters.  
 
2.16 mRNA Sequencing Analysis 
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SW620 and SW620/Ad300 cells were treated with vehicle control or100 nM of MX106-
4C for 72 h. At the end of treatment, the total RNA of each group was extracted using the 
RNeasy Plus Mini Kit (Qiagen, Hilden, Germany).  Total RNA concentrations and purity 
were determined by the OD260nm and the ratio of OD260nm/OD280nm.  The quality of 
the RNA samples was further assessed by electrophoresis on a denaturing agarose gel to 
confirm the integrity of RNA and no DNA contamination. The RNA samples were 
subjected to cDNA library construction and Illumina NovaSeq 6000 conducted at 
Novogene Corporation Inc. (Durham, NC, USA).  The mRNA profiles were compared 
between cells incubated with MX106-4C and vehicle, as well as between SW620 and 
SW620/Ad300 cells. Differentially expressed genes (DEGs) with a significance level of 
p<0.05 and fold change >2 between groups were screened for Kyoto Encyclopedia of 
Genes and Genomes KEGG pathway enrichment analysis through performed through the 
online accessible DAVID Bioinformatics Resources 6.8 (NIAID/NIH, 
https://david.ncifcrf.gov). Graphical visualizations of data were carried out using 
GraphPad Prism 8 software (GraphPad Software, La Jolla, CA) for the volcano plots, 
Bioinformatics online platform (http://www.bioinformatics.com.cn/en) for cluster 
heatmaps and enrichment bubble plots, and KEGG Mapper tool 
(https://www.kegg.jp/kegg/mapper) for color-annotated KEGG pathway maps. 
 
2.17 Reverse Phase Protein Array (RPPA) 
SW620 and SW620/Ad300 cells were treated with vehicle control or 200 nM of MX106-
4C for 72 h. After treatment, total protein lysate was prepared, quantified, and gradiently 
diluted. The diluted samples were subjected to the RPPA processed by Mills Institute for 
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Personalized Cancer Care, Fynn Biotechnologies Ltd. (Shandong, China), including 
printing of diluted protein lysates on a nitrocellulose membrane chip, blotting with primary 
and secondary antibody, scanning for luminescence signal, and normalization of 
expression data. A protein expression file of 307 cancer-related genes was generated for 
each treatment group. Identification of DEGs and bioinformatic analysis were carried out 
as described in section 2.16. 
 
2.18 Growth and Drug Sensitivity of 3D Multicellular Tumor Spheroids (MCTSs) 
Cells were seeded into 1% agarose-coated 96-well plates in a density of 500 cells/well for 
SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells, and in a density of 1500 
cells/well for HCT-15 and HCT-15-ABCB1ko cells. The MCTSs were treated with 300 
nM MX106-4C at 48 h post-seeding of the cells when the MCTS aggregates formed to 
approximately 300 to 400 µm in diameter. The images of the MCTSs were taken with an 
inverted phase-contrast microscope and the diameters of the MCTSs were measured at time 
points 0, 24, 48, and 72 h.  
 
2.19 Statistical Analysis 
Statistical analysis was carried out in the GraphPad Prism 8 software (GraphPad Software, 
La Jolla, CA). Comparisons between mean values of multiple groups were carried out using 
one-way ANOVA and the subsequent Tukey’s post hoc test. Dunnett’s post hoc test was 
used after ANOVA when multiple groups were compared with one control group. 
Comparisons between mean values of HCT-15 cells and HCT-15-ABCB1ko cells were 
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Table 1. List of primers used for qPCR analysis.  
Gene Forward primer (5’-3’) Reverse primer (5’-3’) 






BIRC5 TGACGACCCCATAGAGGAAC CGCACTTTCTCCGCAGTTTC 
TP53 TTTGAGGTGCGTGTTTGTGC TGTTGTTGGGCAGTGCTCG 
CDKN1A TGTCCGTCAGAACCCATGC AAAGTCGAAGTTCCATCGCTC 
CDK4 GTCTATGGTCGGGCCCTCTG TCAGATCAAGGGAGACCCTCAC 
CDK6 TGGCTCTAACCTCAGTGGTCG GGCAACATCTCTAGGCCAGT 
CCND1 GATCAAGTGTGACCCGGACTG AAAATGCTCCGGAGAGGAGG 
FAS GACCCTCCTACCTCTGGTTCTT TGTGCAGTCCCTAGCTTTCC 
GADD45A AGAGCAGAAGACCGAAAGGATG TACACCCCGACAGTGATCGT 
GADD45B CCTGCAAATCCACTTCACGC CGTGTGAGGGTTCGTGACC 
GADD45G GAAAGCGCTGCATGAGTTGC ATTGTCGGGGTCCACGTTC 




CHAPTER 3 RESULTS 
3.1 Selectively Cytotoxic Effect of Compound MX106-4C against ABCB1 
Overexpressing Cells 
In order to investigate the selective toxicity of compound MX106-4C against ABCB1 
overexpressing cancer cells, two pairs of cell lines consisting of drug-sensitive parental cell 
lines and the derived drug-selected ABCB1 overexpressing MDR sublines were tested. As 
summarized in Table 2, although anticancer drug doxorubicin and survivin inhibitor YM-
155 exhibited higher efficacy than MX106-4C in inhibiting the cell viability of parental 
cancer cell lines KB-3-1 and SW620, their cytotoxic effects were sharply reduced in MDR 
cell lines KB-C2 and SW620/Ad300. On the contrary, MX106-4C showed approximately 
10-fold higher potency in ABCB1 overexpressing cell lines KB-C2 and SW620/Ad300 
compared to the parental cell line KB-3-1 and SW620. Cisplatin, which is not a substrate 
of ABCB1, showed similar sensitivity in drug resistant cells and the parental cells. These 
results confirmed that ABCB1 overexpression was the major contributor to the resistance 
to substrate drugs doxorubicin and YM-155 in KB-C2 and SW620/Ad300 cells, meanwhile 
indicated that MX106-4C may not be a substrate of ABCB1 but selectively toxic to MDR 
cells with ABCB1 overexpression.  
 
To further confirm the role of ABCB1 overexpression in the selective toxicity of compound 
MX106-4C, ABCB1 gene transfected HEK293/ABCB1 and the vector control 
HEK293/pcDNA3.1 cells were subjected to cytotoxicity testing. Similar results were 
observed from HEK293/ABCB1 and HEK293/pcDNA3.1 cells: HEK293/ABCB1 cells 
were resistant to doxorubicin and YM-155 but not to cisplatin compared to 
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HEK293/pcDNA3.1 cells, and collaterally sensitive to compound MX106-4C with a fold 
resistance as low as 0.01 was shown in HEK293/ABCB1 cells. This suggested that ABCB1 
is a major factor contributing to the selective toxicity of MX106-4C in ABCB1 
overexpressing MDR cells. 
 
Resistance to chemotherapy mediated by ABCB1 in colon cancer can be intrinsic due to 
endogenous ABCB1 expression. To determine whether compound MX106-4C has a high 
inhibitory effect on non-selected ABCB1 positive colon cancer cells, the HCT-15 cell line, 
which is known to have intrinsic overexpression of ABCB1, was tested. The result showed 
that, compared to SW620 cells with low ABCB1 expression, HCT-15 cells were 
hypersensitive to MX106-4C, with an IC50 value as low as 0.167 ± 0.018 µM (Figure 3), 
indicating that MX106-4C could be useful not only in treating drug-induced ABCB1 





Table 2. Selective toxicity of compound MX106-4C against ABCB1 overexpressing 
cell lines and the parental cell lines. 
Treatment 
IC50 ± SDa (µM) Fold 
Resistanceb KB-3-1 KB-C2 
MX106-4C 4.3267 ± 0.9471 0.3777 ± 0.0582 0.09 
YM-155 0.0049 ± 0.0005 37.2953 ± 3.9711 7549.38 
doxorubicin 0.0366 ± 0.0070 1.6902 ± 0.4412 46.18 
cisplatin 1.1479 ± 0.1292 1.7318 ± 0.1113 1.50 
 SW620 SW620/Ad300  
MX106-4C 0.6755 ± 0.2027 0.0664± 0.0462 0.10 
YM-155 0.0039 ± 0.0007 23.3681 ± 2.3697 5931.42 
doxorubicin 0.1032 ± 0.0164 15.2409 ± 1.8908 147.68 
cisplatin 1.7948 ± 0.0571 5.1210 ± 0.6467 2.85 
 HEK293/pcDNA3.1 HEK293/ABCB1  
MX106-4C 0.2426 + 0.0579 0.0033 ± 0.0006 0.01 
YM-155 0.0034 ± 0.0014 47.0512 ± 6.5968 13978.47 
doxorubicin 0.0742 ± 0.0106 0.2655 ± 0.0432 3.58 
cisplatin 2.2929 ± 0.4799 2.3310 ± 0.4873 1.02 
a IC50: concentration that reduces cell viability by 50% (mean ± SD). Values in the table 
are determined from at least three independent experiments conducted in triplicate. 
b Resistance Fold represents the IC50 value of the drug from ABCB1 overexpressing cells 





Figure 3. Cytotoxicity of compound MX106-4C on colon cancer cells. 
The IC50 values of MX106-4C for SW620, SW620/Ad300, and HCT-15 cells were 
determined by MTT assay. Columns and error bars represented mean ± SD of IC50 values 




3.2 Intracellular Accumulation of Compound MX106-4C in ABCB1 Positive 
Colon Cancer Cells 
To investigate whether the selective toxicity of compound MX106-4C is contributed by 
elevated MX106-4C concentration in ABCB1 overexpressing cells, the intracellular 
accumulation of compound MX106-4C was determined and compared between SW620 
and SW620/Ad300 cells. As shown in Figure 4, the amount of MX106-4C in cells 
remained at a comparable level with 2 h and 4 h exposure. The intracellular accumulation 
of MX106-4C in SW620 cells was slightly higher than that in SW620/Ad300 cells but the 
difference was statistically insignificant, indicating that ABCB1 expression did not affect 
the intracellular level of compound MX106-4C. The higher toxicity of MX106-4C in 
ABCB1 overexpressing SW620/Ad300 cells was not likely to be associated with uptake or 









Figure 4. Intracellular Accumulation of Compound MX106-4C in SW620 and 
SW620/Ad300 Cells.  
LC-MS/MS detection of intracellular accumulation of MX106-4C in SW620 and 
SW620/Ad300 cells after 2 h and 4 h exposure to 1 µM MX106-4C. Data were normalized 
by the protein content of each sample. Columns and error bars represented average values 




3.3 Interaction of Compound MX106-4C and ABCB1 in Colon Cancer Cells 
3.3.1 Effect of Compound MX106-4C on the Function of ABCB1 
The effect of compound MX106-4C on the function of ABCB1 was investigated by 
ABCB1 ATPase assay and [3H]-paclitaxel accumulation and efflux assay. Unlike 
paclitaxel, which is an ABCB1 substrate that can stimulate ABCB1 ATPase activity, 
compound MX106-4C at up to 10 µM did not have a significant effect on ABCB1 ATPase 
activity (Figure 5), confirming that MX106-4C is not likely to be a substrate of ABCB1. 
Furthermore, this result suggested that the collateral sensitivity of MX106-4C was not 
through disturbing the ATP hydrolysis function of ABCB1. Consistent with the 
observation that MX106-4C neither inhibited nor stimulated ABCB1 ATPase, MX106-4C 
did not have significant effects on the efflux function of ABCB1. After exposure to 50 nM 
of MX106-4C for 72 h, the intracellular [3H]-paclitaxel level remained at approximately 
the same level as the corresponding control group for SW620 and SW620/Ad300 cells, 
respectively (Figure 6A).  The low retention of [3H]-paclitaxel due to ABCB1 exporting 
activity in SW620/Ad300 cells was not significantly affected by MX106-4C (Figure 6B). 
On the contrary, the ABCB1 inhibitor tariquidar, at the same concentration of 50 nM, could 
significantly increase the intracellular accumulation and then decelerate the efflux of [3H]-
paclitaxel in SW620/Ad300 cells. The [3H]-paclitaxel accumulation in SW620 cells was 
also elevated by tariquidar to a small extent, possibly because of the inhibition of the 
endogenous expression of ABCB1 in SW620 cells. As indicated by the negative results 
observed from the MX106-4C-treated group compared to the tariquidar-treated group, 





Figure 5. Effect of compound MX106-4C on vanadate (Vi)-sensitive ABCB1 ATPase 
activity.  
The effect of compound MX106-4C (0-10 µM) on ABCB1 ATPase activity was depicted 
as changes in the percentage of basal ATPase activity as concentration changed. Paclitaxel, 
as an ABCB1 substrate that can stimulate ABCB1 ATPase activity, was used as a positive 
control. Data points and error bars represented the average value and SD obtained from 







Figure 6. Effect of compound MX106-4C on intracellular accumulation and efflux of 
[3H]-paclitaxel.   
(A) The intracellular accumulation of [3H]-paclitaxel in SW620, and SW620/Ad300 after 
72 h exposure of vehicle control, 50 nM MX106-4C or 50 nM tariquidar. * p < 0.05 
compared to control group. (B) The [3H]-paclitaxel efflux activities of SW620 and 
SW620/Ad300 after 72 h exposure of vehicle control, 50 nM MX106-4C or 50 nM 
tariquidar. Data represented the mean ± SD of three independent experiments. 
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3.3.2 Effect of Compound MX106-4C on the Subcellular Localization of ABCB1  
Since the function of ABCB1 was not affected by compound MX106-4C, the selective 
toxicity may be related to the change of subcellular localization or expression of ABCB1. 
Therefore, the immunofluorescence assay was performed to investigate the effect of 
compound MX106-4C on the distribution of ABCB1 expression in cells. As illustrated in 
Figure 7, the overexpression of ABCB1 on the plasma membrane in SW620/Ad300 cells 
was confirmed by the higher green fluorescence intensity compared to the parental SW620 
cells. For 72 h exposure to 50 nM of MX106-4C, the subcellular localization of ABCB1 
was not significantly altered, which remained majorly on the cell membrane. A higher 
concentration of MX106-4C at 100 nM exerted more observable toxicity to SW620/Ad300 
cells as indicated by the cell swelling phenomenon, however, the ABCB1 expression 
(fluorescence intensity) and subcellular localization did not show obvious change 





Figure 7. Effect of compound MX106-4C on the subcellular localization of ABCB1 in 
SW620/Ad300 cells determined by immunofluorescence staining.  
ABCB1 and DAPI fluorescence micrographs were combined to create a merged image. 
ABCB1 expression was shown in green and cell nuclei were stained blue by DAPI. The 
parental SW620 cells were used to compare and confirm the ABCB1 overexpression in 





3.3.3 Effect of Compound MX106-4C on the Expression Level of ABCB1 
To further investigate whether compound MX106-4C affects the expression of ABCB1 in 
colon cancer cells at the transcriptional level as well as protein level, RT-qPCR and 
Western blotting were carried out with drug-selected ABCB1 positive SW620/Ad300 cells 
and intrinsically ABCB1 positive HCT-15 cells. As demonstrated in Figure 8A, from 24 h 
to 72 h, MX106-4C at 100 nM significantly downregulated ABCB1 mRNA level in 
SW620/Ad300 cells to a level comparable to the parental SW620 cells. A similar result 
was observed from and HCT-15 cells. The down-regulating effect of MX106-4C on 
ABCB1 mRNA level was time-dependent in HCT-15 cells (Figure 8B), whereas this time-
dependent pattern was not obvious in SW620/Ad300 cells. Albeit a significant reduction 
in ABCB1 mRNA level was induced by MX106-4C, the protein expression of ABCB1 was 
almost unchanged in MX106-4C-treated SW620/Ad300 and HCT-15 cells (Figure 8 C, D). 
Considering that change in protein expression level may require a longer time to be 
observable after transcriptional alternation, the ABCB1 protein level was determined in 
SW620/Ad300 and HCT-15 cells after extended exposure to compound MX106-4C for up 
to 14 days. After long-term treatment, the ABCB1 protein expression was significantly 
downregulated in SW620/Ad300 and HCT-15 cells (Figure 9). As the transcriptional 
activity but not the function and expression of ABCB1 was not affected by MX106-4C in 
short-term exposure, and change in ABCB1 protein expression required prolonged 






Figure 8. Effect of short term (0-72 h) exposure to MX106-4C on the expression of 
ABCB1 in colon cancer cells.  
(A) (B) The mRNA expression levels of the ABCB1 gene are normalized by the expression 
of the GAPDH gene. Relative mRNA expression was presented as fold change versus 
SW620 (A) or HCT-15 control (B). * p < 0.05 compared to SW620/Ad300 control group 
(A) or compared to HCT-15 control group (B). (C) (D) Western blotting results of ABCB1 
protein expression level change after short-term exposure to 100 nM MX106-4C. GAPDH 
was used as a loading control. Relative ABCB1 protein expression was presented as fold 
change versus SW620/Ad300 control (C) or HCT-15 control (D). Columns and error bars 




Figure 9. Effect of long-term (14 days) exposure to MX106-4C on the expression of 
ABCB1 in colon cancer cells.  
Western blotting results of ABCB1 protein expression level change after 14-day exposure 
to 100 nM MX106-4C. Protein extraction was done at the end of the 14-day incubation. 
GAPDH was used as a loading control. Relative ABCB1 protein expression was presented 
as fold change versus HCT-15 control. Columns and error bars represented mean values 




3.3.4 Association between ABCB1 Expression and the Selective Toxicity of Compound 
MX106-4C 
In order to verify the role of ABCB1 expression in MX106-4C-induced selective toxicity, 
the ABCB1 gene knockout sublines of SW620/Ad300 and HCT-15 cell lines were 
established and tested.  The knockout of the ABCB1 gene in SW620/Ad300 and HCT-15 
cells was verified by the ABCB1 protein expression detected using Western blotting 
(Figure 10A) and by ABCB1 mRNA expression determined using RT-qPCR (Figure 10 B, 
C). MTT cytotoxicity test showed that ABCB1 gene knockout re-sensitized SW620/Ad300 
and HCT-15 cells to ABCB1 substrate drug doxorubicin (Figure 11B), while the response 
to non-substrate drug cisplatin was unaffected (Figure 11C), which confirmed the loss of 
ABCB1 in the knockout cell lines.  Significantly reduced sensitivity of SW620/Ad300 and 
HCT-15 cells to MX106-4C (Figure 11A) was observed. The SW620/Ad300-ABCB1ko 
cells were even more unresponsive to MX106-4C compared to SW620 cells, possibly due 
to the endogenous ABCB1 expression in SW620 as confirmed in Figure 10B. These results 






Figure 10. Confirmation of ABCB1 knockout in SW620/Ad300 and HCT-15 cells.  
(A) Western blotting results of ABCB1 protein expression level in cells. GAPDH was used 
as a loading control. (B) (C) The mRNA expression levels of the ABCB1 gene measured 
by RT-qPCR normalized by the expression of the GAPDH gene. (B) Relative mRNA 
expression was presented as fold change versus SW620. * p < 0.05 compared to SW620. 
# p < 0.05 compared to SW620/Ad300. (C) Relative mRNA expression was presented as 
fold change versus HCT-15. * p < 0.05. Columns and error bars represented mean values 





Figure 11. Effects of ABCB1 gene knockout on drug sensitivity of colon cancer cells.  
The IC50 values of (A) MX106-4C, (B) doxorubicin, and (C) cisplatin in SW620/Ad300 
and HCT-15 cells were determined by MTT assay. Columns and error bars represented 
mean ± SD of IC50 values acquired from three independent experiments in triplicate. * p 





3.3.5 Contribution of ABCB1 Efflux and ATP Hydrolysis Function to the Selective Toxicity 
of Compound MX106-4C 
As the dependence of MX106-4C selective toxicity on ABCB1 expression has been 
suggested, whether this selective toxicity requires functional ABCB1 was investigated. 
Tariquidar, a third-generation ABCB1 inhibitor, was used to inhibit the ABCB1 efflux 
function in cytotoxicity tests with MX106-4C. In order to exclude the possible direct toxic 
effect from tariquidar, the selected concentration 1 µM for tariquidar had been confirmed 
to be non-toxic and effective in inhibiting ABCB1 function in preliminary tests before 
reversal study was performed. As expected, inhibition of ABCB1 using tariquidar resulted 
in an effective reverse of doxorubicin resistance in SW620/Ad300 cells (Figure 12B) and 
HCT-15 cells (Figure 12 E), while the IC50 values of cisplatin remained approximately the 
same (Figure 12 C, F). With ABCB1 function blocked by tariquidar, SW620, 
SW620/Ad300, and HCT-15 cells became significantly less sensitive to MX106-4C 
(Figure 12 A, D), suggesting that functional ABCB1 was necessary for compound MX106-
4C to induce selective toxicity.  
 
The roles of ABCB1 efflux function and ATP hydrolysis function in selective toxicity of 
MX106-4C were further examined respectively using HeLa S3 cells expressing wild-type 
(WT) ABCB1, TM6,12-14A mutant ABCB1 with impaired efflux and acquired uptake 
function, and TM6,12-14A-EQ mutant ABCB1 with deficient ATPase function. The 
untransduced HeLa S3 cells without ABCB1 expression were used as a control. The results 
showed that the TM6,12-14A mutant was less sensitive to MX106-4C compared to cells 
with WT ABCB1, whereas the TM6,12-14A-EQ mutant was even more irresponsive with 
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an IC50 value comparable to the untransduced cells (Figure 13 A, B). This suggested that 
the hypersensitivity to compound 4C is dependent on the drug efflux activity of ABCB and 





Figure 12. Reversal effects of tariquidar on drug sensitivities of colon cancer cells.  
The MTT assay-determined IC50 values of (A) (D) MX106-4C, (B) (E) doxorubicin, (C) 
(F) cisplatin in SW620, SW620/Ad300, and HCT-15 cells with or without the presence of 
1 µM tariquidar. Columns and error bars represented mean ± SD of IC50 values acquired 





Figure 13. Cytotoxicity of compound MX106-4C compound in untransduced HeLa 
S3 cells and HeLa S3 cells expressing wild-type (WT), TM6,12-14A, or TM6,12-14A-
EQ mutant ABCB1.  
This result was provided by Drs. Suresh V. Ambudkar and Hadiar Rahman in National 
Cancer Institute. (A) The cell viability changes in response to 48-h exposure to various 
concentrations of MX106-4C were determined by Cell Titer-Glo viability assay. 
Untransduced cells (UN) were used as a control. Data points with error bars displayed the 
average viability (%) ± SD obtained from at least three independent experiments performed 
in triplicate. (B) The IC50 values (mean with SD) of MX106-4C were obtained from Hela 









3.4 Effect of Compound MX106-4C on Cell Apoptosis and Cell Cycle in ABCB1 
Positive Colon Cancer Cells 
As a survivin inhibitor, compound MX106-4C may affect cell apoptosis or cause cell cycle 
arrest by inhibiting survivin. To investigate whether the selective toxicity of compound 
MX106-4C is correlated to survivin inhibition, the cell apoptosis and cell cycle were 
assessed in MX106-4C-treated colon cancer cells. In addition, the effect of MX106-4C on 
survivin expression and the downstream effector caspases-3/7 in colon cancer cells was 
determined. 
 
3.4.1 Effect of Compound MX106-4C on Cell Apoptosis 
As shown in Figure 14, compound MX106-4C increased the rate of apoptosis in ABCB1 
overexpressing SW620/Ad300 cells in a concentration-dependent manner; however, this 
effect was abolished by knocking out the ABCB1 gene from SW620/Ad300 cells. There 
was also a decrease in the percentage of the viable cells with the treatment of compound 
MX106-4C in SW620 cells compared to the control group, but not as severe as in 
SW620/Ad300 cells. These results revealed that MX106-4C selectively induced apoptosis 





Figure 14. Effect of MX106-4C on cell apoptosis in SW620, SW620/Ad300, and 
SW620/Ad300-ABCB1ko cells.  
(A) Representative scatter plots of PI (y-axis) vs FITC-annexin V (x-axis). Cells were 
classified as viable cells (Annexin V−, PI−), early apoptotic cells (Annexin V+, PI−), late 
apoptotic/necrotic cells (Annexin V+, PI+), and damaged cells (Annexin V−, PI+). (B) The 
bar graph represented the percentage of viable, early apoptotic, and late apoptotic/necrotic 
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cells, respectively. Columns and error bars represent the average cell population (%) and 
the SD obtained from three independent experiments. * p<0.05 and ** p<0.01 compared 




3.4.2 Effect of Compound MX106-4C on Cell Cycle 
On treatment with 50 nM and 100 nM of compound MX106-4C for different exposure time 
lengths, a significant decrease in the percentage of cells at the G2/M phase was observed 
in ABCB1 overexpressing SW620/Ad300 cells compared to the control group (Figure 15). 
It was also shown that compound MX106-4C induced G0/G1 phase arrests in 
SW620/Ad300 cells at 50 nM 48 h and 100 nM 72 h. Interestingly, opposite effects were 
observed in MX106-4C-treated SW620 cells compared to the MDR cells. Accumulation at 
the G2/M phase and decreased population at G0/G1 phase were found in SW620 cells after 
exposure to MX106-4C. In addition, when comparing the control groups, SW620 cells had 
more cell population at the G2/M phase and less cell population at G0/G1 phase than 
SW620/Ad300 cells, while SW620/Ad300-ABCB1ko cells appeared to be more resemble 
that of SW620/Ad300 cells. This indicated that there may be differential expressed genes 
between SW620 and SW620/Ad300 cells related to cell cycle regulation, and those are not 
regulated by ABCB1 so the SW620/Ad300-ABCB1ko cells remain in the same cell cycle 





Figure 15. Effect of MX106-4C on cell cycle in SW620, SW620/Ad300, and 
SW620/Ad300-ABCB1ko cells. 
 (A) Representative histograms of the cell population (y-axis) in respect to PI fluorescent 
intensity (x-axis). (B) The bar graph represented the percentage of cell population at 
G0/G1, S, and G2/M phases, respectively. Columns and error bars represent the average 
cell population (%) and the SD obtained from three independent experiments. * p<0.05 
compared to the control group. 
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3.4.3 Effect of Compound MX106-4C on Survivin Expression 
To further investigate whether the cell cycle arrest and apoptosis induced by compound 
MX106-4C is correlated to repression on survivin expression in colon cancer cells, the 
transcriptional level, as well as protein level of survivin in MX106-4C-treated colon cancer 
cells, were determined. As demonstrated in Figure 16, MX106-4C did not alter the mRNA 
level of survivin (Figure 16A) but could slightly downregulate survivin protein expression 
after 72 h treatment (Figure 16B). As the down regulation of protein expression is not 
significant, compound MX106-4C may have an inhibitory effect on survivin rather than an 





Figure 16. Effect of compound MX106-4C on the expression level of survivin in 
SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells.   
(A) The mRNA expression levels of survivin (BIRC5 gene) in SW620, SW620/Ad300, and 
SW620/Ad300-ABCB1ko cells after 72-h treatment with 50 or 100 nM MX106-4C.  
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Relative mRNA expression was presented as fold change versus SW620 control (ctrl) 
group after normalized by the expression of the GAPDH gene. (B) Western blotting results 
of survivin protein expression level change after short-term exposure to 100 nM MX106-
4C. β-actin was used as a loading control. Relative survivin protein expression was 
presented as fold change versus SW620 control. Columns and error bars represented 





3.4.4 Effect of Compound MX106-4C on Activating Caspases-3/7 
As compound MX106-4C has been shown to selectively induce apoptosis in ABCB1 
positive colon cancer cells, the caspases-3/7 activation as a possible survivin-regulated cell 
apoptosis mechanism was verified by flow cytometry. The result showed that compound 
MX106-4C may increase cleaved caspases-3/7 in ABCB1 overexpressing SW620/Ad300 
cells but not in parental SW620 cells or ABCB1 deficient SW620/Ad300-ABCB1ko cells 
(Figure 17). In addition, the combination of compound MX106-4C with ABCB1 inhibitor 
tariquidar significantly reduced the activation of caspases-3/7 in SW620/Ad300 cells, 
while the active caspases-3/7 levels in SW620 cells and SW620/Ad300-ABCB1ko cells 
were unaffected, suggesting that the cell apoptosis caused by MX106-4C in SW620/Ad300 







Figure 17. The ABCB1-dependent effect of compound MX106-4C on activating 
caspases-3/7 in ABCB1 overexpressing SW620/Ad300 cells.  
The bar graph represented the percentage of cell population with active caspases-3/7 
detections. Columns and error bars represent the average cell population (%) and the SD 







3.5 Oxidative Stress Induced by Compound MX106-4C in Colon Cancer Cells 
3.5.1 Effect of Compound MX106-4C on Intracellular ROS and GSH Levels 
As ROS production and oxidative stress have been considered as a mechanism for CS 
effects, the intracellular ROS levels and GSH levels were detected in colon cancer cells 
treated with MX106-4C. Increased intracellular ROS levels and reduced GSH levels were 
observed in ABCB1 overexpressing SW620/Ad300 cells treated with compound MX106-
4C, following a time-dependent manner but not concentration-dependent manner (Figure 
18A, C). In SW620/Ad300 cells, the intracellular GSH level reduced by MX106-4C could 
be replenished by the addition of 5 mM NAC, a precursor of GSH acting as ROS scavenger, 
but the elevated intracellular ROS levels by MX106-4C were partially revered. These 
phenomena were only presented in ABCB1 overexpressing SW620/Ad300 cells but not 
the parental SW620 or ABCB1 deficient SW620/Ad300-ABCB1ko cells (Figure 18 A, B, 
D), indicating that compound MX106-4C can selectively lead to oxidative stress in ABCB1 







Figure 18. Oxidative stress in SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko 
cell lines upon treatment with MX106-4C.  
(A) Scatter graph of relative intracellular ROS levels. # p<0.05 compared to the control 
group of the corresponding cell line. * p<0.05 compared to the same treatment of the 
parental SW620 cell line. (B)-(D) The relative intracellular GSH levels in SW620 (B), 
SW620/Ad300 (C), and SW620/Ad300-ABCB1ko (D) cells, respectively. * p<0.05 
compared to the control group. Relative intracellular ROS levels and relative intracellular 
GSH levels were calculated by normalizing the ROS (fluorescence intensity) and GSH 
detection (quantified nmole GSH according to standard curve) data using the protein 
content of each sample. The average values and SD obtained from three independent 
experiments were presented. 
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3.5.2 Role of Oxidative Stress in Cell Apoptosis Induced by MX106-4C 
Given that compound MX106-4C could induce oxidative stress on ABCB1 overexpressing 
cells, which could be mitigated by antioxidant NAC, the ability of NAC to counteract 
MX106-4C-induced cytotoxicity and cell apoptosis was then evaluated. The result showed 
that NAC cannot alleviate the cytotoxicity of compound MX106-4C on ABCB1 
overexpressing SW620/Ad300 cells (Figure 19 A). In addition, the combination of 
compound MX106-4C and NAC have no significant difference in cell apoptosis compared 
to MX106-4C alone (Figure 19 B), suggesting that compound MX106-4C-mediated 





Figure 19. Effect of NAC on MX106-4C induced cytotoxicity and apoptosis in SW620, 
SW620/Ad300, and SW620/Ad300-ABCB1ko cells.  
(A) The IC50 values of compound MX106-4C with or without the presence of NAC 
determined by MTT assay. Columns and error bars represented average values and 
standard deviation obtained from three independent measurements in triplicate. (B) 
Representative scatter plots of PI (y-axis) vs FITC-annexin V (x-axis).  
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3.6 Analysis of Transcriptionally Dysregulated Gene Expressions Induced by 
MX106-4C in ABCB1 Overexpressing Colon Cancer Cells 
From mRNA-sequencing analysis, differentially expressed genes (DEGs) with statistical 
significance were selected with p < 0.05, adjusted p value (padj) < 0.05 and fold change > 
2 or <0.5. Following this criterion, 3079 DEGs were found when comparing 
SW620/Ad300 control and SW620 control groups, in which 1389 were upregulated and 
1699 were downregulated (Figure 20A).  In the SW620 MX106-4C group, 337 genes were 
significantly differentially expressed compared to the SW620 control group, with 107 
upregulated and 230 downregulated (Figure 20C). On the contrary, in SW620/Ad300 
MX106-4C group, most DEGs were upregulated when comparing to SW620/Ad300 
control group, with 721 upregulated and 98 downregulated (Figure 20B). Similarly, 2008 
genes were differentially expressed in SW620/Ad300 MX106-4C group compared to the 
SW620 MX106-4C group, mostly (1704 out of 2008) were upregulated (Figure 20D). The 
DEG with the largest fold change is ABCB1, which showed approximately 123.7-fold 
upregulated in SW620/Ad300 control group compared to the SW620 control group. This 
confirmed that the tested samples were reliably reflecting the ABCB1 expression 
difference between parental and resistant cells. The significant DEGs were subjected to 
heat map graphing for comparison among four groups. The heat map of DEGs revealed 
that most genes that were upregulated by MX106-4C treatment in SW620/Ad300 cells did 
not change in the same trend in SW620 cells (Figure 20E). This difference might be 
contributed by the stronger stress induction induced by MX106-4C in ABCB1 
overexpressing SW620/Ad300 cells, or by the altered gene expression profile of 




KEGG pathway analysis for DEGs was used to elucidate the pathways related to the gene 
regulation induced by MX106-4C. The DEGs between SW620/Ad300 MX106-4C group 
and SW620/Ad300 control group were enriched in 28 pathways with p < 0.05 (Figure 21A), 
however, none of these enriched pathways had a padj value <0.05.  On the other hand, both 
DEG lists from SW620/Ad300 vs SW620 and SW620 MX106-4C vs SW620 control got 
only one significantly enriched pathway in the category of KEGG, which is the p53 
signaling pathway (Figure 21 B, C). The p53 pathway is closely associated with cell 
apoptosis and cell cycle regulation. Therefore, dysregulation of the p53 pathway induced 
by MX106-4C may be an important mechanism accounting for the selective toxicity of 
MX106-4C. The DEGs that are involved in the p53 pathway were then summarized in 
Table 3. The trend of expression level changes for the listed gene was validated using RT-
qPCR and further tested in SW620/Ad300-ABCB1ko cells to confirm whether the 
dysregulation of expression induced by MX106-4C is ABCB1-dependent. 
 
RT-qPCR validation tests results showed that TP53 mRNA levels were comparable among 
SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells (Figure 22A). The 
downstream GADD45A gene expression was low in SW620/Ad300 compared to parental 
SW620 and SW620/Ad300-ABCB1ko cells, however, the down regulating trend upon 
treatment with MX106-4C was similar among three cell lines (Figure 22G), which is 
consistent with the sequencing data. Another downstream molecule of p53, GADD45B, 
was shown slightly upregulated at mRNA level in SW620/Ad300 cells, which was 
downregulated as SW620/Ad300 cells were exposed to MX106-4C (Figure 22 H). Since 
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this was inconsistent with the mRNA-sequencing result, and the change was insignificant, 
it was considered that GADD45B mRNA expression may not be affected significantly by 
MX106-4C. As TP53 appeared to be unaffected, whereas the regulation on GADD45A was 
ABCB1-independent, p53 and the downstream GADD45A and GADD45B may not be 
majorly involving factors in the MX106-4C-induced CS effect. CNKN1A (p21) was 
upregulated, and CDK4, as well as CDK6, were downregulated specifically in 
SW620/Ad300 cells (Figure 22 B, C, D), which were consistent with the sequencing data. 
The cell cycle arrest at G0/G1 induced by compound MX106-4C may be explained by the 
dysregulation on p21-CDK4/CDK6 pathway via a mechanism independent of p53. 
Unexpectedly, the encoding gene for cyclin D1, CCND1, showed a high basal expression 
in SW620/Ad300-ABCB1ko cells, which was significantly reduced by MX106-4C (Figure 
22E). As the cell cycle was not shown to be disturbed by MX106-4C in SW620/Ad300-
ABCB1ko cells, further protein level determination is required to investigate this 
inconsistency. Similar to what was found from mRNA-sequencing data, FAS gene 
expression was low in SW620/Ad300 cells and was approximately 2-fold upregulated upon 
exposure to MX106-4C, while the changes in SW620 and SW620-ABCB1ko cells were 
not obvious (Figure 22F). Thus, upregulation of FAS might be involved in MX106-4C 
apoptosis in SW620/Ad300 cells. However, the transcriptional level may not necessarily 






Figure 20. Differentially expressed genes (DEGs) profile by mRNA-sequencing.  
(A)-(D) The volcano scatter plots presented differentially expressed genes between 
different compared groups: SW620/Ad300 control vs SW620 control (A), SW620 MX106-
4C 100 nM 72h vs SW620/Ad300 control (B), SW620 MX106-4C 100 nM 72 h vs SW620 
control (C), and SW620 MX106-4C 100 nM 72h vs SW620 control (D). padj is the adjusted 
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p value. Log2(Fold Change) at -1 and 1, -Log10(padj) at 1.3 were labeled by the dotted 
lines. Differentially expressed genes with fold change >2 or <-2, i.e. Log2(Fold Change)>1 
or < -1, and padj<0.05, i.e. -Log10(padj) >1.3, were selected as significant DEGs for 
heatmap graphing. (E) Heatmap showed significantly DEGs. Heatmap is generated based 
on the fragments per kilobase of transcript per million mapped reads (FPKM) of each gene, 






Figure 21. KEGG pathway enrichment analysis of DEGs from mRNA-sequencing 
analysis.  
KEGG pathway enrichment analysis of DEGs from (A) SW620/Ad300 MX106-4C 100 
nM 72 h vs SW620/Ad300 control comparison, (B) SW620 MX106-4C 100 nM 72 h vs 
SW620 control comparison, and (C) SW620/Ad300 control vs SW620 control comparison. 
The enriched pathways with p<0.05 were shown. An adjusted p value (padj) was obtained 
by the Bonferroni Šidák method as the false discovery rate. The fold enrichment is the ratio 
of (number of input genes involved in this pathway/number of all input genes)/(number of 
genes within this KEGG term on the background list/number of genes on the background 
list ). * padj<0.05. 
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MX106-4C vs control 
SW620/Ad300 
control  
vs SW620 control 
SW620  
MX106-4C vs control 
SW620/Ad300 
MX106-4C  












0.2716 0.0003 0.1816 0.0157 0.3084 2.21E-06 0.1748 0.0104 
p21 
(CDKN1A) 
2.6850 6.78E-37 -3.0099 1.16E-49 - >0.05 - >0.05 
CDK4 -0.5485 8.69E-09 0.4673 8.42E-07 0.1979 0.0484 -0.2584 0.0061 
CDK6 -0.4985 6.27E-16 0.4854 1.32E-15 0.1974 0.0008 -0.1842 0.0018 
Cyclin D1 
(CCND1) 
0.4918 3.45E-16 0.3396 8.65E-07 0.1458 0.0433 0.7166 1.36E-41 
GADD45A 0.4966 2.21E-08 -1.8817 0.0000 -1.2769 1.96E-
110 
- >0.05 
GADD45B 1.3964 8.66E-25 -1.3492 0.0000 -1.5209 1.83E-29 1.6695 4.55E-33 
FAS 1.0069 0.0023 -1.0255 0.0127 -   >0.05 -  >0.05  
apadj: The p values for DEGs were calculated by quasi-likelihood F-test (QLF). Then 








Figure 22. Validation of mRNA-sequencing data by RT-qPCR.  
SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells were treated with vehicle 
control, 50 and 100 nM of MX106-4C, respectively for 72 h. The mRNA expression levels 
were determined using RT-qPCR. Relative mRNA expression was presented as fold 
change versus SW620 control group after normalized by the expression of the GAPDH 
gene. Columns and error bars represented average values and standard deviation obtained 





3.7 Analysis of Dysregulated Protein Expression Induced by MX106-4C in 
ABCB1 Overexpressing Colon Cancer Cells 
Reverse phase protein array (RPPA) was performed to analyze the dysregulated protein 
expression induced by MX106-4C in ABCB1 overexpressing colon cancer cells, and to 
identify the potential mechanism of action. A heatmap was used to compare the 
differentially expressed protein in different groups. Similar to what was observed from 
mRNA-sequencing data, the differentially expressed proteins in SW620/Ad300 MX106-
4C group compared to SW620/Ad300 control mostly had an opposite regulatory pattern to 
the change induced by MX106-4C in SW620 cells. From the heatmap, it can be observed 
that proteins that were upregulated upon MX106-4C treatment in SW620/Ad300 cells were 
mostly unaffected or downregulated upon MX106-4C treatment in SW620 cells (Figure 
23). The different gene expression profiles between SW620/Ad300 cells and parental 
SW620 cells may play an important role in causing the differential response to MX106-4C. 
Besides, cleaved caspase-3, which is the active form of caspase-3 that mediates cell 
apoptosis, was shown to be selectively increased in MX106-4C-treated SW620/Ad300 
cells. This confirmed the previous finding from cell apoptosis assay and caspases-3/7 assay 
that MX106-4C could induced cell apoptosis in ABCB1 overexpressing SW620/Ad300 
cells via activating caspases-3. 
 
The differentially expressed proteins (padj <0.05 with fold change>2 or <0.5) were further 
subjected to KEGG pathway analysis. None of the differentially expressed proteins had 
more than 2-fold change when comparing SW620 MX106-4C groups with the control 
group, and there are only 12 significantly differentially expressed proteins for 
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SW620/Ad300 control vs SW620 control, which is a small list not likely to generate 
reliable KEGG enrichment analysis. Therefore, KEGG enrichment analysis was only 
performed for SW620/Ad300 MX106-4C groups vs SW620/Ad300 control group (36 
entries). The analysis result showed that the p53 pathway was significantly enriched 
(Figure 24), which suggested that the p53 pathway may be involved in MX106-4C induced 
gene dysregulation at the transcriptional level as well as protein level. The differentially 
expressed proteins that are members in the p53 pathway, including all that got p<0.05 with 
or without 2-fold change, were then summarized in Table 4. And the trend of expression 
level change induced by MX106-4C was validated using Western blotting for the listed 
proteins. 
 
As the RPPA only detects 307 cancer-associated proteins and some hits from mRNA-
sequencing may not be included in the list, to further elucidate the involvement of the p53 
pathway in MX106-4C-induced selective toxicity, protein levels of CDK4 and CDK6 were 
also detected. The Western blotting validation tests results showed that p53, p21 and pRb 
protein levels were not significantly changed among the cell lines and treatment groups. 
CDK6 and phospho-pRb proteins were selectively downregulated in ABCB1 
overexpressing SW620/Ad300 cells, which was consistent with the RT-qPCR result and 
the RPPA report, respectively. CDK4 was also downregulated but the effect was not 
specific to ABCB1 overexpressing cells (Figure 25). Therefore, the selectively down 
regulation of CDK6 and phospho-pRb may explain the selective induction on cell cycle 





Figure 23. Differentially expressed protein profile by RPPA.  
(A) Heatmap showed all proteins detected in RPPA. Differentially expressed proteins with 
fold change >2 or <-2, and padj <0.05 in any comparisons were selected as significant data 
for secondary heatmap graphing. (B) The secondary heatmap showed significantly 
differentially expressed proteins with the name of entry at each row. Heatmap is generated 
based on normalized log2 quantified protein expression values (NormLog2). Z score = 




Figure 24. KEGG pathway enrichment analysis of significantly deferentially 
expressed proteins from RPPA analysis for SW620/Ad300 MX106-4C 200 nM 72 h vs 
SW620/Ad300 control comparison.  
The enriched pathways with p<0.05 were shown. An adjusted p value (padj) was obtained 
by the Bonferroni Šidák method as the false discovery rate. The fold enrichment is the ratio 
of (number of input genes involved in this pathway/number of all input genes)/(number of 
genes within this KEGG term on the background list/number of genes on the background 




Table 4. Differentially expressed proteins from RPPA analysis that are involved in 








vs SW620 control 
SW620  
MX106-4C 200 nM 
vs control 
SW620/Ad300 
MX106-4C 200 nM  
vs SW620 MX106-













p53 -1.3831 0.0056 0.0032 0.9759 0.2885 0.1050 -1.6680 0.0050 
p21 0.8925 0.0327 -0.3018 0.0803 0.1922 0.1638 0.3986 0.0716 
cyclin D1 0.3346 0.0025 -0.0598 0.4321 0.2638 0.0913 0.0110 0.5457 
phosphoryla
ted pRb  
(p-pRb 
S807/S811) 









Figure 25. Validation of RPPA data by Western blotting.  
SW620, SW620/Ad300, and SW620/Ad300-ABCB1ko cells were treated with vehicle 
control, 50 and 100 nM of MX106-4C, respectively for 72 h. The protein expression levels 
were determined using Western blotting. Relative greyscale values were shown below each 
band, which were determined by the greyscale of the band normalized by the greyscale of 
the β-actin band on the same PVDF membrane. The greyscale measurements were carried 
out in ImageJ. 
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3.8 Synergistic Effect of Doxorubicin Co-administrated with MX106-4C on 
Inhibiting Colon Cancer Cell Viability 
The combined inhibitory effect of doxorubicin co-administrated with MX106-4C on cell 
viability was assessed in colon cancer cells, including SW620, SW620/Ad300, and HCT-
15 cell lines. As the sensitivities to doxorubicin and MX106-4C are different among the 
cell lines due to different expression levels of ABCB1, the concentrations of doxorubicin 
and MX106-4C were adjusted for each cell line by putting the concentration around IC50 
of single-drug treatment as the median.  As shown in Figure 26A, in SW620 cells, the 
combinations with CI values<1 were mostly observed when doxorubicin concentration was 
0.03 or 0.1 µM and MX106-4C concentration was 0.3 or 1 µM, while other combinations 
had CI values >1 or closed to 1. This suggested that combination effects were 
concentration-dependent. On the other hand, in ABCB1 overexpressing SW620/Ad300 
and HCT-15 cells, most CI values of the combination were less than 1 except for several 
closed to 1 (Figure 26 B, C), indicating that the cytotoxic effects of doxorubicin in 
combination with MX106-4C at the tested concentration ranges could have synergistic 
effect on SW620/Ad300 and HCT-15 cells. The difference between SW620 and the other 
two ABCB1 overexpressing cell lines revealed that MX106-4C may be beneficial to 





Figure 26. The synergistic anti-cancer effect from multiple ratios of MX106-4C and 
doxorubicin in colon cancer cells.  
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Summary tables for (A) SW620, (B)SW620/Ad300, and (C) HCT-15 cell lines showing 
potency (% inhibition), combination index (CI), and combination of MX106-4C and 
doxorubicin combined at various concentrations and ratios. Combinations exhibiting 
synergism (CI<1) were highlighted in the table. Data were the average %inhibition 




3.9 Capability of Compound MX106-4C to Re-sensitize ABCB1 Overexpressing 
MDR Colon Cancer Cells 
As significant down regulation of ABCB1 had been observed after 14-day exposure to 
compound MX106-4C, the alteration on drug sensitivities was further examined to evaluate 
the capability of compound MX106-4C to re-sensitize MDR colon cancer cells. After 14-
day exposure to 100 nM MX106-4C, SW620/Ad300, and HCT-15 cells gained 
approximately 3-fold more resistance to the untreated cells (Figure 27 A, D). Enhanced 
sensitivity to ABCB1 substrate doxorubicin was significant in SW620/Ad300 cells after 
14-day treatment with MX106-4C, while HCT-15 cells got less significantly 
(approximately 2-fold) re-sensitized to doxorubicin by long term exposure to MX106-4C 
(Figure 27 B, D). This was in accord with the difference in ABCB1 protein level in cells 
with or without 14-day exposure to MX106-4C as discussed in section 3.3.3. Cisplatin, 
which is not transported by ABCB1, was used as a negative control. The IC50 values of 
cisplatin stayed at a similar level between treated and untreated groups (Figure 27 C, D). 
These results indicated that the low resistance to MX106-4C and re-sensitization to 
doxorubicin were associated with the decreased ABCB1 protein expression by long-term 






Figure 27. Effect of 14-day exposure to 100 nM MX106-4C on drug sensitivity profile 
of SW620/Ad300 and HCT-15 cells.   
(A)-(C) The IC50 values of (A) MX106-4C, (B) doxorubicin, and (C) cisplatin in SW620, 
SW620/Ad300, and MX106-4C treated SW620/Ad300 cells for 14 days. (D) The IC50 
values of MX106-4C, doxorubicin, and cisplatin in HCT-15 cells with or without 14-day 
treatment with MX106-4C. Columns and error bars represented mean ± SD of IC50 values 
determined by MTT assay from three independent experiments in triplicate. * p < 0.05.  
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3.10 Evaluation on Selective Toxicity of MX106-4C in Colon Cancer Multicellular 
Tumor Spheroids (MCTSs) 
To further evaluate the selective toxicity of MX106-4C on MDR colon cancer cells in a 
tumor structure, the multicellular tumor spheroid (MCTS) model was used to mimic the 
natural biology of tumors. It has been reported that MCTSs could have different sensitivity 
to chemotherapeutic agents compared to 2D monolayer cultured cells because of the 
differential diffusion of drugs in spheroid structure (Han et al., 2021). Therefore, a 
preliminary experiment was used to identify the appropriate concentration of MX106-4C 
in MCTSs tests. Based on the IC50 values obtained from the MTT assay, three 
concentrations (100, 300, 1000 nM) were tested in a preliminary experiment, and 300 nM, 
which was neither too toxic nor too ineffective to all spheroids, was selected for further 
experiment.  
 
As depicted in Figure 28A, MX106-4C at 300 nM induced significant growth inhibition in 
SW620/Ad300 spheroids, whereas the growth of spheroids from SW620 and 
SW620/Ad300-ABCB1ko cells was hardly affected.  SW620/Ad300 spheroids treated with 
MX106-4C had a significantly smaller increase in the diameter of the cell aggregates 
compared to the control group (Figure 28B). HCT-15 spheroids treated with MX106-4C 
also showed slower growth in diameter compared to the control group, while the growth 
HCT-15-ABCB1ko spheroids were not affected by 300 nM MX106-4C (Figure 28C). 
Besides of the growth retardation effects, another major observation from HCT-15 
spheroid treated with MX106-4C was the less aggressive growth pattern compared to the 
control group (Figure 28A). The hypersensitivity to MX106-4C in ABCB1 overexpressing 
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spheroids was consistent with the cytotoxicity effects observed from the MTT assay, 
suggesting that the selective toxicity of MX106-4C observed from cell-based assays could 




Figure 28. Growth retardation induced by compound MX106-4C in multicellular 
tumor spheroids (MCTSs) of colon cancer cell lines.  
(A) Representative images of the MCTSs treated with either vehicle control (culture media) 
or 300 nM MX106-4C at time points 0, 24, 48, and 72 h. Scale bar represented 200 µm. 
(B) (C) Change of MCTSs volumes after treatment. Percentage of MCTSs volume was 
calculated by (spheroid volume – spheroid volume at timepoint-0)/spheroid volume at 





3.11 Evaluation on Cytotoxicity of MX106-4C on Normal Colon Cells  
To evaluate the safety of compound MX106-4C, cytotoxicity tests were performed using 
human normal colon fibroblast cells, CCD-18Co. As shown in Figure 29, the inhibitory 
effect of MX106-4C on the viability of CCD-18Co cells was less significant compared to 
the three colon cancer cell lines tested (Figure 29). The selectivity index (SI = IC50 from 
normal cells ÷ IC50 from cancer cells) (Badisa et al., 2009)  was calculated to determine 
the selectivity of MX106-4C against cancer cells. An SI value higher than 2 suggests 
selective toxicity against cancer cells and relative safety in normal cells (Awang et al., 
2014). As demonstrated in Table 4, the SI values of CCD18Co versus SW620/Ad300 was 
10.1 and that of CCD18Co versus HCT-15 was 5.7, indicating that the selectivity of 
MX106-4C was good against ABCB1 positive colon cancer cells. Since MX106-4C is a 
collateral sensitivity agent, the IC50 value of MX106-4C from SW620 cells with low 
ABCB1 expression was closer to that from CCD18Co cells, leading to a smaller SI value 





Figure 29. Comparison on the cytotoxicity of compound MX106-4C against colon 
cancer cell lines and normal colon cell line.  
The cell viability changes in response to various concentrations of MX106-4C were 
determined by MTT assay.  Data points with error bars displayed the average viability (%) 




Table 5. Cytotoxicity of Compound MX106-4C to Normal Colon Cell Line and 
Selectivity against Colon Cancer Cell Lines 
Cell line MX106-4C IC50a (nM) Selectivity index (SI)b 
CCD-18Co 551.95 ± 65.03 - 
SW620 294.47 ± 58.27 1.9 
SW620/Ad300 54.66 ± 4.13 10.1 
HCT-15 99.25 ± 15.06 5.7 
a IC50: concentration that reduces cell viability by 50% (mean ± SD). Values in the table 
are determined from at least three independent experiments conducted in triplicate. 




CHAPTER 4 DISCUSSION 
The ABCB1 expression is closely correlated with MDR in colorectal cancer, therefore, 
various approaches to suppress ABCB1 have been developed extensively investigated. As 
the outcomes for applications of ABCB1 inhibitors in clinical settings have been 
disappointing, novel strategies are urgently required for surmounting ABCB1-mediated 
cancer MDR, such as to develop novel CS agents that are selectively toxic to ABCB1 
overexpressing cancer cells. In this study, the selective toxicity of compound MX106-4C 
against ABCB1 positive colon cancer cells was characterized and the mechanism of the 
selective toxicity was investigated.  
 
In the cytotoxicity test, the ABCB1 overexpressing MDR cell lines exhibited resistance to 
ABCB1 substrate doxorubicin and YM155, while cisplatin, which was used as a non-
substrate control of ABCB1, had similar cytotoxic effects on both parental and resistant 
cell lines. This confirmed the ABCB1-mediated MDR characteristics of the cell models 
utilized in the present study. MX106-4C appeared to be a potent CS agent for both 
intrinsically ABCB1 positive colon cancer HCT-15 cells and acquired ABCB1 
overexpressing colon cancer SW620/Ad300 cells. Sensitivities of cancer cells towards a 
chemotherapeutic agent are usually correlated with the intracellular concentration. For 
example, ABCB1 substrates like doxorubicin have low efficacy in ABCB1 overexpressing 
MDR cancer because of the reduced intracellular accumulation mediated by ABCB1 efflux 
activity (Shen et al., 2008). However, the accumulation level of compound MX106-4C was 
shown to be comparable in ABCB1 overexpressing SW620/Ad300 cells and the parental 
SW620 cells, suggesting that the selective toxicity of MX106-4C was not contributed by 
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increased drug accumulation but by enhanced activities of MX106-4C specifically in 
ABCB1 positive colon cancer cells. Therefore, MX106-4C is likely to target a biological 
molecule that is overexpressed in ABCB1 positive cells or target hyperactive biological 
events that are dependent on ABCB1 or other molecules overexpressing simultaneously 
with ABCB1.  
 
From the previous reports, the selective toxicities of CS agents are generally ABCB1-
dependent, which could be abrogated by applying an ABCB1 inhibitor or silencing ABCB1 
(Callaghan et al., 2014; Ludwig et al., 2006; Nakagawa-Goto et al., 2010). Depending on 
the drug properties, CS agents may interact with ABCB1 directly as a substrate or inhibitor, 
respectively resulting in stimulation on ATP hydrolysis and ROS production (Jansson et 
al., 2015; Laberge et al., 2009), or inhibiting ABCB1 function thereby disturbing ABCB1-
dependent events that are involved cell survival (Kuo et al., 2011). Hence, interaction with 
ABCB1 was considered as a possible mechanism of action for MX106-4C. Functional 
assays measuring ABCB1 mediated drug efflux and ATPase activity were carried out. The 
ABCB1 drug efflux activity can be affected by a substrate or an inhibitor with ATPase 
stimulating effect or inhibitory effect, respectively (Nandigama et al., 2019).  MX106-4C 
neither stimulated nor inhibited the ATPase activity of ABCB1, and it did not affect the 
ABCB-mediated [3H]-paclitaxel efflux activity, suggesting that it may not be a substrate 
or typical inhibitor of ABCB1. Nevertheless, the results that the collateral sensitivity effect 
of MX106-4C can be reversed by applying ABCB1 inhibitor tariquidar, ABCB1 knockout, 
or ABCB1 dysfunction mutant indicated a dependence relationship between MX106-4C-
mediated CS effect and functional ABCB1 expression. Therefore, it is likely that MX106-
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4C did not interact with ABCB1 directly but interacted with downstream molecules or 
events that require functional ABCB1.  
 
In particular, it was shown that the TM6,12-14A mutant with impaired efflux function but 
normal ATPase function only partially reversed the selective toxicity of MX106-4C, 
whereas the TM6,12-14A-EQ mutant with deficient ATPase function completely abolished 
the selective toxicity, indicating a critical contribution of ATP hydrolysis in the CS effect 
of MX106-4C. The involvement of ABCB1-mediated ATP hydrolysis in CS effects has 
been associated with ROS production (Efferth et al., 2020; Pluchino et al., 2012). The 
hypothetical mechanism is that when the cells continue to replenish the ATP consumed by 
ABCB1 ATPase, ADP passes oxidative phosphorylation thereby generating ROS to 
supplement ATP (Karwatsky et al., 2003). As expected according to the finding that the 
CS effect of MX106-4C required ABCB1 ATPase activity, it was observed that MX106-
4C could increase ROS generation in SW620/Ad300 cells but not in parental SW620 cells 
or ABCB1 deficient SW620/Ad300-ABCB1ko cells. Although MX106-4C was shown to 
have no direct stimulation on ABCB1, the assay using insect cell membranes may not truly 
reflect the ABCB1 ATPase in viable cancer cells. Since exporting activity and ATPase 
function are suggested as requirement for MX106-4C-induced CS effect, it can be 
hypothesized that substrate efflux activity of ABCB1 consuming ATP is ongoing during 
the process where MX106-4C exerts toxic effect to cells, thereby generating ROS. The 
possibility that MX106-4C causes generation or release of physiological ABCB1 substrate 
in cells to indirectly stimulate ABCB1 ATPase cannot be excluded. Further direct 
investigation on ATP consumption and ABCB1 ATPase activity is required for 
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confirmation. The induced ROS production may be a possible explanation for the 
observation of cell swelling from immunofluorescence microscopic images of 
SW620/Ad300 cells treated with 100 nM MX106-4C for 72 h, because ROS accumulation 
is known to be correlated with mitochondria dysfunction such as calcium overload, 
mitochondrial permeability transition, and morphological alteration of mitochondria, 
which can lead to oncosis-like cell death (Du et al., 2010; Guo et al., 2013). Nevertheless, 
whether mitochondria damage is involved in the selective toxicity of MX106-4C requires 
further investigation. Albeit increased ROS production in MX106-4C-treated 
SW620/Ad300 cells, this was suggested to be a minor factor in MX106-4C-mediated 
selective toxicity, because coadministration of ROS scavenger NAC replenished 
intracellular GSH but failed to counteract the cytotoxicity of MX106-4C. The ROS 
production may be an accompanied phenomenon of ABCB1 activity, which may act as 
synergistic contributor rather than major contributor to the cytotoxicity of MX106-4C. 
 
Additionally, MX106-4C may potentially regulate ABCB1 expression. It was found that 
short-term (up to 72 h) exposure to 100 nM MX106-4C downregulated ABCB1 expression 
at mRNA level but not protein level, while long-term (14 days) exposure significantly 
reduced ABCB1 protein expression. Similar effects have been reported for the other CS 
compounds, NSC73306 and KP772, which caused loss of ABCB1 protein expression 
respectively in HCT-15 cells after three weeks exposure (Ludwig et al., 2006) and in KBC-
1 cells after 20 passages selection (Heffeter et al., 2007). However, little was known about 
the mechanism for down regulating ABCB1 expression in long term exposure. It could be 
possible regulation on gene expression pre-transcriptionally. Another possibility is the 
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selection pressure from MX106-4C. In the field of cancer chemotherapy, it has been 
suggested that drug resistance can arise through continuous selection for cells that display 
higher drug tolerance, which exhibited a higher stability compared to the sensitive cells 
and survive upon subsequent cell divisions (Bell & Gilan, 2020). Therefore, the loss of 
ABCB1 expression during long-term exposure could also be contributed by survival 
advantages of colonies with low ABCB1 expression and further flourishment of such 
colonies. Further experiment with monitoring on ABCB1 expression in cells from the 
beginning of exposure may help elucidate this question.  
 
Besides interaction with ABCB1, the interaction of MX106-4C with survivin, which is its 
designated target, may also contribute to the CS effects. Survivin functions as an inhibitor 
of apoptosis mainly by binding and inhibiting the activation of caspases-3 and 7 (Garg et 
al., 2016). In addition, survivin plays a regulatory role in cell cycle progression. It has been 
reported that overexpression of survivin in human hepatoma cells could interaction with 
CDK4, thereby counteracting G1 arrest and accelerate S phase shift (Suzuki et al., 2000). 
In order to investigate whether survivin inhibition is involved in the selective toxicity of 
MX106-4C, the effects of MX106-4C on cell cycle arrest, cell apoptosis and expression of 
survivin were investigated. The result that MX106-4C induced cell apoptosis and cell cycle 
arrest at G0/G1 indicated survivin inhibition effect exerted by MX106-4C at 100 nM. The 
increased level of the active form of caspases-3/7, which are the effector of survivin, were 
observed in MX106-4C-treated SW620/Ad300 cells, further confirming survivin inhibition 
in SW620/Ad300 cells. However, unlike MX106 or other analogs that can degrade survivin 
(Wang et al., 2018), MX106-4C did not alter the expression of survivin, which suggested 
 
 93 
that the inhibitory effect may be functional inhibition instead of regulation on the survivin 
expression. It is also possible that the concentration used is relatively low thus it is not 
potent enough to degrade survivin. Interestingly, although the survivin expression levels 
were comparable among SW620, SW620/Ad300 and SW620/Ad300-ABCB1ko cells, the 
cell cycle arrest at G0/G1 phase and cell apoptosis induced by MX106-4C at 100 nM 
selectively occurred in ABCB1 overexpressing SW620/Ad300 cells. Besides, the enhanced 
activity of cleaved caspases-3/7 in SW620/Ad300 cells could be attenuated by ABCB1 
inhibitor tariquidar. This inferred that the survivin functional inhibition by MX106-4C was 
also ABCB1 dependent, by which it may be able to explain why there was mild apoptosis 
induction in SW620 cells with low ABCB1 expression compared to the unaffected 
SW620/Ad300-ABCB1ko cells. Unexpected increase in cell populations at G2/M phase 
was observed in parental SW620 cells treated with MX106-4C. As the ABCB1 knockout 
subline of SW620/Ad300 did not have this type of response, the G2/M phase arrest in 
SW620 cells induced by MX106-4C is not likely to be correlated with ABCB1 expression. 
It may be caused by differential expressions of certain cell cycle modulating molecules 
between SW620 and SW620/Ad300 cells occurred during doxorubicin selection. 
Nevertheless, the type of cell cycle change appeared to have minimal influence on causing 
cell death in SW620 cells. 
 
Further bioinformatics analysis revealed that the p53 pathway may be an important player 
in MX106-4C induced cell cycle arrest and apoptosis. Vital molecules involved in this 
process may include p21, CDK4, CDK6, and phosphorylated pRb. CDK4/6 are cyclin-
dependent kinases responsible for regulating the cycle progression from the G1 phase to 
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the S phase by binding to cyclin D and inactivating phosphorylation of the central tumor 
suppressor pRb (Bonelli et al., 2019). The downstream effector pRb protein, as a tumor 
suppressor, is responsible for G1 checkpoint by blocking S-phase entry to negatively 
control the cell cycle, preventing the uncontrolled proliferation of tumor cells (Giacinti & 
Giordano, 2006). Phosphorylation on serine-807 and serine-811 of pRb induced by 
CDK4/6-cyclinD complex leads to functional inactivation of pRb, resulting in cell cycle 
progression (Brantley & Harbour, 2000), while induction of dephosphorylation leads to 
apoptosis (Adegbola & Pasternack, 2005). On the other hand,  p21(Cip1/Waf1), which is 
encoded by the gene CDKN1A, is a CDK inhibitor that regulates cell cycle progression 
(Wade Harper, 1993). It has been found that p21 has a complex regulatory function on 
CDK4/6: it can bind to CDK4/6-cyclinD1 complex, which stabilized and inactivated 
CDK4/6 function to negatively regulate the G1 to S phase shift; it may in contrast activate 
CDK4/6 at low level (Karimian et al., 2016).  These cell cycle regulatory molecules may 
have interactions with survivin. Survivin could interact with CDK4, leading to pRb 
phosphorylation (Suzuki et al., 2000). Survivin/CDK4 complex formation may induce p21 
released from its complex with CDK4 and interacts with mitochondrial procaspase 3 to 
suppress Fas-mediated cell death (Suzuki et al., 2000). As supported by the bioinformatic 
analysis data and further validation results, MX106-4C may induce cell apoptosis and 
G0/G1 arrest in SW620/Ad300 cells via down regulating CDK4 and CDK6 leading to 
hypophosphorylation of pRb. Although the change in p21 protein level was insignificant, 
it is still possible that p21 is involved in MX106-4C-mediated cell apoptosis mechanism. 
Inhibition of survivin by MX106-4C may result in caspase-3-activated cell apoptosis by 




It was clearly observed that functional ABCB1 expression is required for MX106-4C-
mediated cell apoptosis, cell cycle arrest, and the underlying CDK6 inhibition, pRb 
dephosphorylation and caspase-3 activation, However, little has been revealed regarding 
the precise role of ABCB1 efflux function and ATP hydrolysis in these selective effects 
from MX106-4C. One possible explanation may be the ABCB1-dependent expression of 
tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). It has been 
reported that functional ABCB1 plays a critical role in TRAIL expression, and inhibition 
of ABCB1 activity could induce TRAIL expression and reduce binding of the TRAIL 
ligand to death receptors (Souza et al., 2015). Survivin was also found to inhibit TRAIL-
induced apoptosis (Azuhata et al., 2006). As mutual regulations between survivin and 
ABCB1 has been found on transcriptional levels but not on translational or post-
translational levels in cancer cells (Liu et al., 2010; Shi et al., 2007), survivin and ABCB1 
might interact indirectly via involved signaling pathways like the TRAIL apoptotic 
pathway. It may be hypothesized that MX106-4C could be involved in multiple 
mechanisms such as triggering TRAIL-related apoptotic signal transduction, which 
requires an intracellular environment with functional ABCB1, meanwhile causing survivin 
inhibition that enhanced the activity of the apoptotic signal pathway. Further study is 
needed to elucidate the roles of ABCB1 and survivin in the CS effect of MX106-4C. 
 
Finally, as a CS agent, the potential of MX106-4C to synergistically inhibit heterogenetic 
tumors with conventional anticancer drugs and to re-sensitize heterogenetic tumors to 
ABCB1 substrate drug were proved. As long-term exposure to MX106-4C caused 
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significantly reduced expression of ABCB1 in the cell population, it is reasonable that 
MX106-4C could re-sensitize colon cancer cells to doxorubicin. Furthermore, considering 
the limitation of 2D monolayer cell culture that the monolayer culture cells do not reflect 
the natural structures of tumors and the cell-cell or cell-extracellular environment 
interactions, and that the drug diffusion patterns are altered (Kapalczynska et al., 2018), 
the 3D MCTSs model was used to mimic the tumor growth and sensitivity to MX106-4C 
in vitro. It was proved that the selective toxicity of MX106-4C in vitro can be retained in 
the 3D spheroid setting. It is encouraging that MX106-4C exhibited a good selectivity 
against ABCB1 positive colon cancer cells and was relatively safe to normal colon cells. 
Nevertheless, the normal cell line tested was colon fibroblast, whereas ABCB1 is 
physiologically majorly expressed on the apical epithelial cells of colon tissue (Holohan et 
al., 2013). Therefore, the toxicity of MX106-4C on colon cells expressing ABCB1 remains 
uncertain. Future study should focus on further evaluation of the anti-cancer efficacy and 




CHAPTER 5 SUMMARY 
It has been characterized in this study that MX106-4C is a potent CS agent, which 
selectively kills ABCB1 positive cells without affecting ABCB1 functions or subcellular 
localization. Mechanistic study findings are illustrated in Figure 30. The selective toxicity 
of MX106-4C is dependent on ABCB1 expression and requires functional ABCB1, 
particularly the ATP hydrolysis, which could explain the ROS production induced by 
MX106-4C in ABCB1 overexpressing cells. In addition, the selective cytotoxic effects of 
MX106-4C could be associated with ABCB1-dependent functional inhibition on survivin, 
leading to cell cycle arrest at G0/G1 phase and cell apoptosis, possibly via modulation on 
p21-CDK4/6-pRb phosphorylation pathway and activation of caspases-3/7.  However, it 
remains a lot to be elucidated regarding the precise role of ABCB1 in MX106-4C-mediated 
cell apoptosis, cell cycle arrest, and the molecular alterations on corresponding pathways.  
 
As a CS agent, MX106-4C can be useful to treat colon cancer by synergistically killing 
cancer cells when administrated with doxorubicin or re-sensitizing ABCB1 overexpressing 
cells to substrate chemotherapeutic drugs. And most importantly, it has good selectivity for 
ABCB1 positive colon cancer cells compared to normal colon cells.  
 
Future studies will focus on further elucidation on the mechanism of action for MX106-4C 
induced CS effect, particularly how ABCB1 function contributes to the toxicity effect. 
Meanwhile, evaluation of the anti-cancer efficacy and safety of MX106-4C using in vivo 




Figure 30. Graphical summary of possible mechanisms involved in MX106-4C-
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